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Renin is the first and rate-limiting step of the renin-angiotensin system. The exclusive 
source of renin in the circulation are the juxtaglomerular cells of the kidney, which 
line the afferent arterioles at the entrance of the glomeruli. Normally, renin produc-
tion by these cells suffices to maintain homeostasis. However, under chronic stimu-
lation of renin release, for instance during a low-salt diet or antihypertensive therapy, 
cells that previously expressed renin during congenital life re-convert to a renin-pro-
ducing cell phenotype, a phenomenon which is known as “recruitment”. How exact-
ly such differentiation occurs remains to be clarified. This review critically discusses 
the phenotypic plasticity of renin cells, connecting them not only to the classical 
concept of blood pressure regulation, but also to more complex contexts such as de-
velopment and growth processes, cell repair mechanisms and tissue regeneration.
1- Introduction
The renin-angiotensin system (RAS) plays a central role in blood pressure reg-
ulation and fluid-electrolyte homeostasis. It involves an array of enzymes, peptides 
and receptors with endocrine, paracrine and autocrine functions, whose actions are 
able to correct small extracellular volume (ECV) variations by increasing or decreasing 
RAS activity. According to the classical, endocrine view of the RAS, also known as the 
systemic RAS, renin, synthesized in the kidneys, catalyzes cleavage of a 10-amino acid 
peptide, angiotensin I, from the N-terminus portion of the circulating angiotensino-
gen, a protein produced by the liver. This decapeptide is subsequently hydrolyzed by 
angiotensin I-converting enzyme (ACE), a dicarboxyl-peptidase ubiquitously present 
on the plasma membrane of endothelial cells, yielding the octapeptide angiotensin 
II, the active endproduct of the RAS cascade, which is responsible, among others, for 
sodium reabsorption in the proximal convolute tubule of the nephron, and for ves-
sel constriction, especially arterioles within the renal and systemic circulation [1]. This 
traditional axis was completed later, with the discovery of aldosterone. Angiotensin II 
stimulates the zona glomerulosa in the adrenal cortex to release aldosterone, which 
promotes sodium reabsorption coupled with potassium exchange in the distal con-
volute tubule of the nephron. The whole axis, named renin-angiotensin-aldosterone 
system (RAAS), is now firmly linked to ECV adjustment and blood pressure regulation 
[2]. However, in the last three decades, the RAS has assumed an even bigger role, in 
that it also participates in the pathophysiology of renal and cardiovascular diseases, 
through its inflammatory and pro-fibrotic actions. As a consequence, RAS blockade 
now is a cornerstone in the treatment of renal and cardiovascular diseases [3, 4]. The 
RAS also contributes to normal and abnormal growth processes and, evolutionary, the 
growth-promoting actions of angiotensin precede its endocrine and paracrine effects, 
representing one of its most highly conserved functions [5]. 









In 1898, Tigerstedt and Bergman performed a set of experiments, where they 
observed a rise in blood pressure after injecting rabbit kidney extracts in the jugular 
vein of rabbits. They characterized the substance as derived from the renal cortex, sol-
uble in water and alcohol, thermolabile, and named it “renin”. This discovery remained 
dormant for more than 40 years, until a few decades ago research finally started to 
focus on renin [6]. Renin represents the first and the rate-limiting step of the RAS cas-
cade. Overproduction and underproduction of renin result in severe disturbances of 
body fluid homeostasis. Precise regulation of renin release is therefore indispensable 
for proper RAS functioning [1, 7]. Renin is an aspartyl protease synthesized as an in-
active zymogen, prorenin. The kidney secretes both renin and prorenin, but plasma 
levels of prorenin are, under normal conditions, about 10-fold higher than the plasma 
levels of renin [8]. Renin consists of 2 homologous lobes, with a cleft in between, which 
contains the active site. Prorenin has a 43-amino acid N-terminal propeptide, which 
covers the enzymatic cleft between the 2 lobes, thereby preventing the access of its 
specific substrate, angiotensinogen. Prorenin is a glycoprotein, which can be activated 
in 2 ways: proteolytically or non-proteolytically. The former is irreversible and involves 
removal of the propeptide by a processing enzyme, while the latter is reversible, in-
ducible by certain conditions such as low temperature and pH, and results from a con-
formational alteration, i.e., unfolding of the propeptide from the enzymatic cleft [9]. 
3 – Juxtaglomerular Cells (JGC)
The JGC of the kidney are the only source of renin and the main source of pro-
renin in the circulation [1, 10]. Several extrarenal tissues, such as the adrenal gland, 
ovary, testis, placenta and retina, additionally produce and secrete prorenin [8]. In-
deed, after a bilateral nephrectomy, prorenin, but not renin, can still be detected at 
low levels in blood [11]. Following its synthesis, prorenin enters the Golgi apparatus 
to be glycosylated, and then proceeds to one of two different pathways. The first one 
involves clear vesicles containing prorenin which are secreted constitutively, while the 
second pathway involves prorenin tagging for regulated secretion, which is accompa-
nied by proteolytic prorenin-renin conversion, and renin storage in dense cytoplasmic 
granules [10], awaiting release in response to various stimuli, such as a sudden fall in 
blood pressure, a low salt diet, or b-adrenergic stimulation [12].
JGC are part of the juxtaglomerular apparatus, a tight structure situated on the 
kidney glomerular hilum, composed mainly of specialized epithelial cells (macula den-
sa cells of the ascending limb of the nephron loop), extraglomerular mesangial cells, 
the terminal portion of the afferent arterioles and the proximal portion of the efferent 
arterioles. JGC are within these vessels and exhibit an epithelioid appearance, with a 
prominent endoplasmic reticulum, Golgi apparatus, and renin granules, but also con-
taining myofibrils and adhesion plaques, typical of smooth muscle cells [13]. 
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Efforts to characterize JGC have historically been hampered by several factors: 
JGC lose their secretory granules and, concomitantly, their ability to proteolytically ac-
tivate prorenin when placed in culture [14]; JGC make up approximately 1/1000 of the 
total cell mass of the kidney, making it difficult to isolate sufficient quantities of pure 
cells for further characterization [15].
4 – JGC Progenitors and their Embryology
JGC represent one type of the so-called repertoire of renin-producing cells 
(RPC), a group of cells that at some moment in their lifespan produce renin. During kid-
ney ontogeny in mammals, renin expression changes according to a pattern (Figure 1). 
It first appears in the undifferentiated metanephric blastema before vessel formation 
has begun. Once the vascularization begins, around the 14th embryonic day in mice 
and rats, RPC are distributed along the walls of the arteriolar vessels. As the process 
evolves, renin starts to be expressed in other cells along the distal portions of the new-
ly formed vessels. Gradually, RPC disappear from the larger vessels, shifting toward the 
afferent arterioles, and, finally, assuming their position on the juxtaglomerular appara-
tus [12]. Gomez et al. showed that the ontogeny of renin expression by RPC depicts its 
own phylogenetic evolution pattern [16].
The expression of the renin gene is tissue-specific and developmentally regulat-
ed [17]. Renal renin concentrations are high in early life, decreasing progressively as kid-
ney maturation evolves [18]. During this process, RPC are associated with assembling 
and branching of the developing kidney vasculature [19], and the ablation of these 
cells in mice during development results in a distinct kidney phenotype with peculiar 
vascular abnormalities [20]. In vivo, vascularization of the kidney is synchronized with 
epithelial nephrogenesis [21]. Epithelial branching morphogenesis is critical for the 
formation of various organs, including the vasculature and kidneys [22]. The definitive 
kidney in mammals originates from a complex interaction between the ureteric bud 
and the metanephric mesenchyme, both derived from the intermediate mesoderm. 
These reciprocal actions lead the ureteric bud to elongate and bifurcate toward the me-
tanephric mesenchyme, forming on its tip, an aggregate of mesenchyme cells, the cap 
mesenchyme. This condensate of cells generates a vesicle, which continues to form a 
comma-shaped body and later, a S-shaped body that gives rise to most of glomerulus 
and tubular epithelia. As nephrogenesis progresses, the newly formed S-shaped body is 
fused to the ureteric bud, from which the collecting ducts and ureter originate [23, 24].
Cap mesenchyme expresses the transcriptional factors Six2 and Cited1 and 
gives rise to Bowman’s capsule, podocytes, the proximal and distal convolute tubules 
and the loop of Henle. There is an outer layer of loose mesenchyme cells, adjacent to 
the cap mesenchyme, which expresses different transcriptional factors: cKit (endothe-
lial precursors) or forkhead box D1 (FoxD1, stromal cells). The latter factor is respon-
sible for the generation of RPC, mesangial cells and all mural cells, including vascular 
smooth muscle cells (VSMC), perivascular fibroblasts and pericytes [25-27]. 
Figure 1. Schematic illustration of nephrogenesis. The ureteric bud (UB) interacts with 
the methanephric mesenchyme (MM), resulting in the subsequent formation of the 
cap mesenchyme (CM) and loose mesenchyme (LM). The CM harbors the transcription 
factors Six2 and Cited1 (in orange), and will give rise to the tubular system (proximal 
convolute tubule (PCT), loop of Henle (LH) and distal convolute tubule (DCT); the LM 
harbors the transcriptions factor FoxD1 (depicted in green), and will give rise to most of 
the glomeruli and vascular cells from the afferent arteriole (AA) and efferent arteriole (EA). 
The UB will evolve to from the collecting duct (CD) and ureter. Modified from [21, 24, 33].
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5- The Recruitment Phenomenon  
JGC lineage involves differentiation of the above metanephric mesenchymal 
cells. This complex process generates hemangioblasts, which will evolve to endothelial 
cells, and RPC precursors, the latter harboring the transcriptional factor FoxD1. During 
kidney ontogeny, these precursors will give rise to JGC and a subset of VSMC [25, 27]. 
In the adult, stress events that threaten body homeostasis, such as hypotension or 
extracellular fluid depletion, are normally corrected through renin release by JGC. Nev-
ertheless, if this response does not suffice, or if renin expression is chronically stim-
ulated, VSMC along the preglomerular arterioles undergo metaplasia to a renin cell 
phenotype in order to also synthesize renin, a phenomenon known as “recruitment” 
[28] (Figure 2). Importantly, the upregulation of renin synthesis and release following 
a homeostasis threat is due to a rise in the number of RPC (hyperplasia) rather than an 
elevation on the renin production per cell (hypertrophy) [29, 30]. 
The recruitment phenomenon is an indispensible mechanism to maintain ho-
meostasis. In the 1970s, Cantin et al. observed metaplasia of VSMC into JGC in the 
arteries and arterioles of ischemic kidneys [31]. Nowadays, it is known that this trans-
formation involves differentiation of a non-renin-expressing cell into a phenotype 
that is able to synthesize renin, and occurs in the descendants of cells that previously 
expressed renin during development [32]. Interestingly, once the stimulation perpet-
uates, the recruitment intensifies, and RPC may occur all along the extension of pre-
glomerular arterioles, larger vessels, in the extraglomerular and intraglomerular me-
sangium, in a pattern that resembles the development of the embryonic kidney [32]. 
In a recent review, Gomez emphasized that recruitment does not involve migration or 
replication of cells, but solely concerns a phenotype switch toward renin expression 
by cells whose capability to produce renin is latent, and re-acquired following appro-
priate stimulation [33].
Nevertheless, Dzau et al. identified liver X receptor alpha (LXRα), a nuclear re-
ceptor, as an important player in the induction of renin expression in JGC. They showed 
that LXRα exerts its activity as a cAMP-responsive regulator, binding to a unique up-
stream region of the renin promoter [34]. LXRα activation additionally upregulated a 
set of genes (e.g., c-myc) that are involved in cellular differentiation, proliferation and 
migration. Accordingly, LXRα would induce JGC hypertrophy and hyperplasia, through 
its coordinate interaction on the renin and c-myc promoters [29]. 
Moreover, mesenchymal stem cells (MSC) have also been suggested to play a 
pivotal role in the recruitment phenomenon. Matsushita et al. demonstrated that hu-
man and murine MSC are capable of synthesizing renin following LXRα activation. 
Indeed, MSC overexpressing LXRα and under continuous cAMP stimulation 
underwent differentiation to a RPC phenotype, which could also express α-smooth 
muscle actin (αSMA) [35]. Thus, on the basis of these findings, it was speculated that 
MSC, which are normally resident within the glomerulus, might be the origin of the 
RPC [35]. Wang et al. used cell lineage tracking models to further study the role of 
MSC in RPC recruitment. First, they isolated MSC from the adult mouse kidney and 








verified the expression of typical tissue stem/progenitor cell markers, including CD44, 
and of metanephric mesenchymal cell markers, such as FoxD1. CD44-positive MSC-
like cells differentiated into RPC following exposure to an LXRα agonist, cAMP or a 
phosphodiesterase inhibitor [36]. Furthermore, mice submitted to a low salt diet and 
captopril treatment, conditions well-established to induce JGC recruitment, exhibited 
an expansion of RPC in the kidney, accompanied by CD44 cells, with co-localization 
of MSC markers and renin. These results could not be reproduced with bone marrow 
MSC, suggesting that only MSC resident in the adult kidney contribute to JGC recruit-
ment [36]. The prostaglandin E2/E-prostanoid receptor 4 pathway, also known for its 
involvement in tubuloglomerular feedback, played a key role in the activation of renal 
CD44-positive MSC during conditions of JGC recruitment [37]. 
 
However, the participation of adult renal MSC in JGC recruitment has been 
questioned. Gomez et al. reported that MSC at most have a very minor contribution 
in comparison with the already existing pool of arteriolar cells undergoing a pheno-
type switch [33]. The latter authors ascertained that JGC also express CD44, so that it 
is questionable whether MSC truly represent a different cell group in the recruitment 
process, or are just simply descendants of the renin cell lineage, capable of switching 
Figure 2. The ‘recruitment’ phenomenon, illustrated by a schematic illustration (panels A 
and C) and immunofluorescence and fluorescent in situ hybridization data from control and 
captopril-treated mice (panels B and D, modified from [64]). In adult kidneys, renin is produced 
by the juxtaglomerular (JG) cells located within the afferent arterioles at the entrance of the 
glomeruli. However, under chronic renin stimulation (e.g., following captopril treatment), renin 
lineage cells (like the vascular smooth muscle cells (VSMC)) along the afferent arterioles may 
convert into a renin-producing cell (RPC) phenotype in order to maintain the homeostasis. 
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their renin phenotype back and forth. Moreover, CD44 expression on MSC might be an 
in vitro artifact, since  primary MSC from bone marrow lacked such expression, while it 
did occur after culturing the cells [38]. Further studies are needed to unravel the pre-
cise role of MSC in JGC recruitment.          
6- cAMP Pathway and Recruitment 
Renin is a cAMP-inducible gene. In all species tested, there is a functional cAMP 
response element on the renin promoter [12]. Among all the intracellular second mes-
sengers that control renin secretion, the cAMP signaling cascade appears to be the 
core pathway for the exocytosis of renin [10, 39, 40] (Figure 3). Thus, prostaglandins, 
kinins, and β-adrenergic agonists have a stimulatory effect on renin release, in all cases 
because they increase cAMP generation [41].
cAMP regulates a wide range of biological processes in cells. The binding of an 
extracellular signal molecule to a G-protein coupled receptor activates adenylyl cy-
clase (AC), an enzyme that generates cAMP from ATP, increasing its intracellular levels. 
This rise activates cAMP-dependent protein kinase A (PKA). PKA translocates to the nu-
cleus to phosphorylate the gene regulatory protein CREB (cAMP responsive element 
binding protein). CREB recognizes a specific DNA sequence, called the cAMP response 
element (CRE), found in the regulatory region of many genes. Once phosphorylated, 
CREB recruits the coactivator CBP (CREB-binding protein), which stimulates gene tran-
scription [42].
Interestingly, conditional deletion of G-protein subunits in RPC has a great 
impact on their function. Indeed, mice with protein Gsα (stimulatory subunit α) de-
ficiency in JGC have very low plasma renin concentrations, with resulting low levels 
of aldosterone and arterial blood pressure. Moreover, such deletion also resulted in 
abnormalities in the preglomerular arterial tree [43, 44]. 
Elegant evidence on the regulation of renin production by cAMP was obtained 
by Gomez et al., who labeled cells of renin lineage with cyan fluorescent protein (CFP), 
and cells producing renin with yellow fluorescent protein (YFP) [45]. This yielded suit-
able amounts of cells which could still produce renin after several passages. CFP-la-
beled cells expressed VSMC markers like α-SMA and smooth muscle myosin heavy 
chain (SM-MHC or Myh11), but not renin. However, after stimulation with forskolin (an 
AC stimulator) or cAMP analogs, they began to express YFP and renin, and decreased 
α-SMA and Myh11 expression. This response was even bigger with more intense or 
longer stimuli, suggesting that the recruitment response is graded [45].
7- Role of calcium and cGMP
Calcium plays an important role in the biology of secretory cells. In general, a 
rise in cytosolic calcium leads to the release of their content. However, the opposite 
occurs in parathyroid cells and JGC, where calcium inhibits renin exocytosis. This is 








known as the “calcium paradox”, and it remained as a mystery for decades [41, 46]. 
JGC harbor 2 isoforms of AC (types V and VI), which are inhibited by cytoso-
lic calcium. Thus, particularly in JGC, a decrease in cytosolic calcium would stimulate 
AC, resulting in cAMP synthesis and, consequently, renin release [47, 48]. Initially, it 
had been reported that calcium inhibits renin gene transcription and destabilizes re-
nin mRNA [49]. More recently, it became clear that calcium stimulates, via the calci-
um sensing receptor, a calcium calmodulin-activated phosphodiesterase 1C (PDE1), 
an enzyme that degradates cAMP, thereby providing an additional explanation of the 
calcium paradox [50]. 
 
Figure 3. Simplified scheme showing how cAMP and cGMP regulate renin (modified 
from [33]). ATP, adenosine-triphosphate; cAMP, cyclic adenosine-monophosphate; 
AC, adenylate cyclase; CBP, CREB-binding protein; CREB, cAMP response element 
binding protein; cGMP, cyclic guanosine-monophosphate; PDE, phosphodiesterase; 
NO, nitric oxide; pGC, particulate guanylate cyclase; sGC, soluble guanylate cyclase; 
GPRC, G-protein-coupled receptor; Gsα, stimulatory G protein α-subunit; Gβ, inhibitory 
G protein β-subunit; Gγ, inhibitory G protein γ-subunit; PKA: protein kinase A.
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The contribution of cGMP to renin release is more complex, with both stimula-
tory and inhibitory effects [46]. The cGMP and cAMP pathways are cross-linked. Nitric 
oxide (NO) activates soluble guanylate cyclase (GC) to generate cGMP, which in turn 
inhibits phosphodiesterase 3, a cAMP-degrading enzyme. Consequently, cAMP levels 
will go up, and renin release will rise [46, 51]. However, ligands that increase cGMP 
via activation of particulate GC (like atrial natriuretic peptide) inhibit renin exocytosis 
through activation of cGMP-dependent protein kinase type II [10, 46]. Interestingly, 
Neubauer et al. recently demonstrated that RPC recruitment is dependent on NO avail-
ability and the NO-GC signaling pathway [52]. 
8- Epigenetic Mechanisms and microRNA (miRNA) 
Acetylation and deacetylation of histones are important epigenetics mecha-
nisms involved in gene transcription regulation. Acetylation is mediated by histone 
acetyltransferase (HAT), which leads to the transfer of an acetyl functional group to 
histone molecules, promoting nucleosomal relaxation and transcriptional activation. 
Deacetylation is mediated by histone deacetylase (HDAC), and results in chromatin 
condensation and transcriptional repression [53].  
Using the double-fluorescent reporter mouse model described above, Gomez 
et al. observed that chromatin remodeling contributes to the recruitment process, at 
the cAMP level, through histone H4 acetylation [45]. The underlying mechanism in-
volved the CREB-recruited cofactors CBP and p300, which exhibit HAT activity and, 
in the CRE region, promote nucleosomal relaxation and, consequently, transcription-
al activation. In support of this concept, forskolin increased histone H4 acetylation in 
the CRE region [45]. Studies carried out in mice with conditional deletion of CBP and 
p300 in RPC revealed that individual deletion of one of these cofactors did not affect 
renin expression, while simultaneous deletion reduced renin in adult life, and resulted 
in renal interstitial fibrosis [54]. CBP/p300 were also indispensable for re-expression 
of renin in the arteriolar VSMC of mice exposed to low sodium + captopril [55]. Tak-
en together, RPC have a poised chromatin landscape suitable to respond properly to 
threats, allowing these cells to switch the renin phenotype on and off [33].  
In addition to the epigenetic control mechanisms, microRNAs (miRNAs) also 
control JGC activity. miRNAs are endogenous small non-coding RNA molecules, con-
taining around 18-22 nucleotides. They exert their function by targeting mRNA, in-
ducing decay or translational repression [56]. miRNA genes are phylogenetically con-
served, and are involved in many cell processes such as developmental timing, death 
and proliferation [57]. miRNA transcription, usually by RNA polymerase II, results in a 
long transcript, whose structure will be cleaved by the RNase III endonuclease Dro-
sha and the cofactor DGCR8, yielding a miRNA precursor (pre-miRNA). This precursor 
is processed by the RNase III enzyme Dicer, and the product is incorporated into the 
RNA-induced silence complex, where gene silencing proceeds [58]. 
Gomez et al. established the importance of Dicer for the JGC and, even further, 








for the morphologic and physiologic integrity of the kidney. They discovered that con-
ditional deletion of Dicer in cells of the renin lineage in mice reduced the number of 
JGC and decreased renin gene expression, thus leading to reduced plasma renin and 
blood pressure levels. The animals also presented kidneys with vascular abnormalities 
and striped fibrosis [59]. Noteworthy, this vascular pattern was quite similar to that 
found in mice with ablation of the RPC, through the expression of diphtheria toxin A 
chain driven by the renin promoter [20]. Surprisingly, kidney vessels exhibited nor-
mal wall thickness and lumen size, in contrast to the concentric hypertrophy and thick 
vessel walls seen when RAS genes are deleted, including renin. Apparently, RPC are 
responsible for arterial wall thickening, by producing angiogenic and trophic factors 
[20, 21].
Furthermore, Medrano et al. identified two miRNA, miR-330 and miR-125b-5p, 
whose opposite actions are crucial for the recruitment phenomenon. miR-125b-5p is 
normally expressed in the VSMCs of the afferent arteriole, and responsible for sustain-
ing a contractile phenotype. Yet, it is also expressed in JGC, in order to preserve their 
contractile function. However, under a homeostasis threat, miR-125b-5p expression 
diminishes in VSMC, allowing them to undergo a metaplastic transformation into a 
renin phenotype, and remains unaltered in JGC. miR-330 is expressed in JGC only, and 
inhibits contractile features, thus favoring renin production [60]. 
9- JGC Signature: the Myo-endocrine Profile 
Although several factors have been identified that regulate renin production 
and secretion, RPC-specific markers were limited to renin itself, and the gene Zis tran-
script [14]. To overcome this problem, Brunskill at al. targeted YFP to mouse JGC and 
used fluorescence-activated cell sorting (FACS) to enrich tagged cells for transcrip-
tome analysis. This approach yielded a set of 369 core genes, responsible for the JGC 
gene regulatory network [61]. Furthermore, this distinct array of genes that governs 
JGC identity is unique when compared to other cell types in the kidney. Mainly, it en-
compasses genes highly expressed in both smooth muscle and endocrine cells [61].
Among the genes identified in the transcriptome analysis, renin was the high-
est transcribed gene. The second highest one was aldo-keto reductase family 1, mem-
ber B7 (Akr1b7), responsible for detoxification of steroidogenesis products. Akr1b7 is 
a member of aldo-keto reductase superfamily, which reduces harmful aldehydes and 
ketones produced from the breakdown of lipid peroxides to their respective alcohols 
[62]. Remarkably, despite its high expression on JGC, mice with Akr1b7-deficient kid-
neys had no abnormalities in renin production and secretion, while renin deletion also 
did not affect Akr1b7 expression [61, 63]. Therefore, Akr1b7 gene might function as a 
novel JGC marker, independently of renin. Other highly expressed transcripts involved 
genes related to the smooth muscle phenotype, like α-SMA, Myh11 and calponin 
(Cnn1) [61]. 
Interestingly, the aforementioned genetic regulatory network allows RPC to 
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possess either an endocrine or a contractile phenotype. Hence, this bivalent profile 
sustains the ability of RPC to switch phenotype, depending on the situation. Therefore, 
during a homeostasis challenge, renin lineage cells have the gene program to differen-
tiate into an endocrine cell, synthesizing and releasing renin, in order to reestablish the 
homeostasis. Moreover, due to their position, at the glomerular hilum, JGC should also 
retain contractile properties, allowing them to contract or relax and, subsequently, to 
adjust renal blood flow and glomerular filtration rate [33, 61].
Martini et al. performed RNA transcriptome analysis on human reninomas, as an 
approach to further understand JGC biology [64]. Reninomas are rare, renin-producing 
tumors, arising from a proliferation of JGC in the kidney cortex, and are often detected 
because of the appearance of fulminant hypertension in young patients [65, 66]. Deep 
sequencing of 4 human reninomas with subsequent transcript mapping in the kidney 
of mice under different conditions yielded a list of genes (36 of which had never been 
described before) specifically expressed in RPC. When evaluating 10 of these genes 
on (pro)renin producing As4.1 cells, it was observed that platelet-derived growth fac-
tor beta (PDGFB) suppressed (pro)renin release and renin gene expression. Moreover, 
PDGFB-exposed cells displayed a phenotypic shift from myo-endocrine to inflamma-
tory, evidenced by αSMA downregulation and interleukin-6 upregulation, and a more 
elongated shape (Figure 4). Here it should be mentioned that neither conditional dele-
tion of the PDGF receptor in RPC, nor deletion of endothelial PDGFB production affect-
ed the normal development of renal RPC [67]. This may not be too surprising, given the 
fact that PDGFB actually is a negative regulator of renin expression, possibly coming 
into play only under pathological conditions. In summary, the reninoma data provide 
a novel role for PDGFB as a regulator of RPC. 
10- Notch Signaling Pathway
The Notch signaling pathway is a highly conserved system, present in all animal 
species, which plays a pivotal role in local cell-cell communication, determining cell 
fate decisions and controlling patterns formation during ontogenesis. Its dysfunction 
is linked to severe developmental defects and pathologies [68]. The Notch signaling 
cascade starts with the binding of specific ligands to the Notch transmembrane re-
ceptor, leading to cleavage of the intracellular Notch receptor domain (NIC). NIC trans-
locates to the nucleus, where it binds to RBPJ (recombination signal binding protein 
for Ig-κJ region), a transcription factor that normally represses Notch target genes by 
recruiting a co-repressor complex. However, once it is coupled to NIC, RBPJ recruits 
cofactors that activate the transcriptional machinery [69]. 
Interestingly, among the 369 core genes that confer the JGC identity accord-
ing to the approach performed by Brunskill et al., there are members of the Notch 
pathway, including RBPJ [61]. In fact, RBPJ had already been related to RPC plasticity 
by Castellanos Rivera et al. [70]. They generated a conditional knockout (cKO) of RBPJ 
in renin lineage cells. This resulted in a striking reduction in the JGC number and re-








nin expression, with subsequently low plasma renin levels and a low blood pressure. 
Furthermore, under conditions that trigger the recruitment phenomenon, such as so-
dium depletion and captopril treatment, RBPJ-cKO mice were unable to exhibit renin 
expression along the afferent arterioles, i.e., the ability of their VSMCs to regain the 
renin phenotype was impaired. 
Additionally, mice with RBPJ-cKO in renal cells of FoxD1 lineage displayed sig-
nificant renal abnormalities, including a decline in the arteries and arterioles number, 
with a thinner smooth muscle cell layer and renin depletion, further upholding the 
concept that RBPJ is a major determinant of the transformation of FoxD1 cells progen-
itors into a healthy kidney vasculature [71]. Experiments in transgenic renin reporter 
zebrafish fully support the essential role of the Notch signaling pathway for develop-
mental renin expression and its association with proper angiogenesis [72].      
 
RBPJ also has a pivotal role in the maintenance of the JGC myo-endocrine gene 
program. Using a bacterial artificial chromosome reporter, it was observed that RBPJ 
activates the renin promoter directly [15]. A double-fluorescent mice reporter model 
subsequently revealed that RBPJ deletion does not affect RPC endowment. RPC were 
at their proper location, although unable to express renin and Akr1b7, and, surprising-
Figure 4. A, Renin levels in 
medium obtained from renin-
producing As4.1 cells incubated 
for 48 hours with medium 
derived from HEK293 cells 
transfected with platelet-derived 
growth factor beta (PDGFB). 
Renin, α-smooth muscle actin 
(αSMA) and interleukin-6 (IL-
6) gene expression are also 
provided. Data (mean ±SEM of 
n=5-11) are modified from [64], 
and have been expressed as a 
percentage of the levels in cells 
exposed to medium of control-
transfected cells, i.e., cells 
treated with the transfection 
mix, but without cDNA. *P<0.05. 
B and C, As4.1 cells under control 
conditions and after exposure 
to PDGFB (10x magnification). 
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ly, also did not express the VSMC markers α-SMA, Myh11 and Cnn1. Yet, they displayed 
an upregulation of genes related to the immunological system, such as lipocalin-2, 
lysozyme-2, chemokine ligand-9 and interleukin-6 [15]. Furthermore, Belyea et al. 
identified renin progenitors in mouse bone marrow, and found that in the presence 
of RPBJ-cKO in the renin cell lineage, those progenitors gave rise to a very aggressive 
lymphoblastic leukemia [73]. 
JGC are surrounded by multiple cell types, including pericytes, endothelial cells, 
epithelial cells, VSMCs, mesangial cells, and macula densa cells. Direct cell-to-cell in-
teraction will undoubtedly contribute to normal RPC functioning. It is therefore not 
surprising that, among the highly expressed transcripts identified by Brunskill et al. in 
JGC, is connexin 40 [61]. Connexins are transmembrane proteins, six of which assem-
ble to mold a hemichannel. When 2 hemichannels of adjacent cells align, a channel is 
formed which allows the cytoplasma of both cells to connect. A set of these channels 
in parallel builds a gap junction, a structure that permits the cells to share small mol-
ecules and, therefore, to respond to extracellular signals in a coordinated way [16]°. 
Unexpectedly, in mice lacking connexin 40, RPC were found in the periglomerular in-
terstitium, and not at their normal juxtaglomerular location. Besides, the recruitment 
phenomenon (following severe sodium depletion) did not occur at its usual location, 
i.e., in the wall of the upstream preglomerular arterioles [74]. Apparently therefore, 
cell-to-cell communication via gap junctions is essential for the correct juxtaglomeru-
lar positioning and recruitment of RPC. 
11- Plasticity and Regeneration 
More than 100 years have passed since renin’s discovery, and the RAS now 
turns out to have multiple effects beyond its role in blood pressure regulation. As out-
lined in this review, renin cells function as pluripotent progenitors for other kidney 
cells types [32, 75]. Normally, a low perfusion pressure leads to an expansion of RPC. 
Kurt et al. investigated to what degree this relates to hypoxia per se, by deleting the 
von Hippel-Lindau protein in JGC, i.e., the negative regulator of the hypoxia-inducible 
transcriptional factor-2 (HIF-2α). Remarkably, following the upregulation of HIF-2α by 
this procedure, RPC started to express erythropoietin instead of renin, and the normal 
renin upregulation after low salt was no longer seen. In fact, JGC were reprogrammed 
into fibroblast-like cells, expressing collagen I and PDGF receptor b (PDGFR-ß) [76, 77]. 
Clearly therefore, hypoxia-inducible genes are essential for normal development and 
physiologic adaptation of RPC. The upregulated PDGFR-ß expression in these cells is 
in full agreement with the results from the human reninoma studies showing that the 
PDGFB- PDGFR-ß pathway downregulates renin expression [64].  
Pippin et al. proposed that cells of renin lineage present alongside the preglo-
merular arteries participate in the glomerular regeneration after podocyte injury [78]. 
In support of this concept, renin cells from the juxtaglomerular apparatus were shown 
to migrate to the glomerular tuft, in order to replace podocytes [79]. This is quite strik-








ing, since podocytes are normally derived from a different embryonic structure, the 
cap mesenchyme cells.
Easier to understand is the participation of renin progenitors in glomerular 
mesangium regeneration, since mesangium cells, considered as specialized pericytes, 
are derived from FoxD1 stromal cells present at the loose mesenchyme. Indeed, in a 
mesangiolysis murine model, renin lineage cells repopulated the intraglomerular me-
sangium [80]. Interestingly, these cells stopped producing renin and expressed PDG-
FR-ß, i.e., the receptor linked to renin downregulation [64]. Furthermore, Stefanska et 
al. established that pericytes are RPC in the human kidney [81]. Traditionally, pericytes 
are perivascular cells that wrap around blood capillaries. They are highly plastic cells 
contributing to multiple processes like angiogenesis, tumorigenesis and vasculopathy 
progression [82]. The concept that RPC are or derive from pericytes is very interesting, 
since pericytes possess regenerative potential and are additionally known for the fact 
that they express the PDGFR-ß [81]. In fact, in zebrafish, Rider et al. observed that renin 
cells express this marker [83].   
12- Concluding Remarks   
How exactly renin cells are able to differentiate into many different phenotypes 
remains to be clarified. The signals allowing RPC to shift phenotype, or to migrate to 
an injury site are now only beginning to be unraveled. Many questions still need to be 
answered, most importantly, whether regeneration would eventually allow a resto-
ration of normal function. This is of particular relevance in chronic glomerulopathies, 
where glomerular cells are destroyed, with subsequent overproduction of extracel-
lular matrix, fibrosis and architectural disruption, all leading to physiological impair-
ment. Apparently, under such severe pathological conditions, tissue regeneration by 
RPCs either does not occur of is insufficient. One possibility is that RPCs under patho-
logical conditions transform to fibroblast-like cells, thus contributing to renal fibrosis 
themselves. Currently, RAS blockade is the cornerstone of renal and cardiovascular 
diseases. Simultaneously, it is well known that RAS blockers, like most anti-hyperten-
sive drugs, induce RPCs recruitment. The long-term effect of this chronic activation is 
still unknown, nor do we know to what degree it contributes to (further) impairment 
of renal function. Detailed knowledge of this process would lead to better treatment 
options and more favorable outcomes. Clearly, this whole area not only illustrates the 
complexity of the renin cell, but also represents an exciting new field that needs to be 
explored in the coming years.
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AIM OF THE THESIS
1) To validate a new approach to understand RPC biology, by using transcriptome 
analysis of human renin-producing tumors (reninoma) (Chapter 2);
2) To evaluate the occurrence of a brain RAS, and subsequently, the potential 
participation of RPC in this process (Chapter 3);
3) To assess whether prorenin in an ‘open’ conformation at the site of its release from 
RPC is capable of generating angiotensin locally (Chapter 4);
4) To investigate renin and prorenin reabsorption in megalin-expressing human 
conditionally immortalized proximal tubule epithelial cells (Chapter 5);   
5) To evaluate, by performing a systematic review and meta-analysis, whether the 
beneficial effects of dual RAS blockade in patients with heart failure and renal 
dysfunction outweigh their side effect profile (Chapter 6).         
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Renin, a key component in the regulation of blood pressure in mammals, is produced 
by the rare and highly specialized juxtaglomerular (JG) cells of the kidney. Chronic 
stimulation of renin release results in a recruitment of new JG cells by the apparent 
conversion of adjacent smooth muscle cells along the afferent arterioles. Because JG 
cells rapidly de-differentiate when removed from the kidney, their developmental 
origin and the mechanism that explains their phenotypic plasticity remain unclear. 
To overcome this limitation we have performed RNA expression analysis on four hu-
man renin-producing tumors. The most highly expressed genes that were common 
between the reninomas were subsequently used for in situ hybridization in kidneys of 
5-day old mice, adult mice and mice treated with captopril. From the top 100 genes, 
10 encoding for ligands were selected for further analysis. Medium of HEK293 cells 
transfected with the mouse cDNA encoding these ligands was applied to (pro)re-
nin-synthesizing As4.1 cells. Among the ligands, only platelet-derived growth factor 
B (PDGFB) reduced the medium and cellular (pro)renin levels, as well as As4.1 renin 
gene expression. Additionally, PDGFB-exposed As4.1 cells displayed a more elon-
gated and aligned shape with no alteration in viability. This was accompanied by a 
downregulated expression of a-smooth muscle actin, and an upregulated expres-
sion of interleukin-6, suggesting a phenotypic shift from myo-endocrine to inflam-
matory. Our results add 36 new genes to the list that characterize renin-producing 
cells and reveal a novel role for PDGFB as a regulator of renin-synthesizing cells. 
INTRODUCTION
The aspartyl protease renin catalyzes the rate-limiting step in the renin-angio-
tensin system (RAS). Renin is produced almost exclusively by so-called juxtaglomerular 
(JG) cells that line the afferent arterioles at their point of entry into the kidney glomer-
uli. JG cells convert renin from its inactive precursor (prorenin) by proteolysis and store 
the resulting active renin in lysosome-like dense cytoplasmic granules whose content 
can be rapidly released in response to such stimuli as a sudden drop in the perfusion 
pressure of the afferent arteriole or beta-adrenergic stimulation. During kidney devel-
opment, renin-producing cells are more broadly distributed along the lumen of the 
nascent arterioles [1] and gradually become restricted to the glomerular poles after 
birth. Prolonged exposure to stimuli, such as blood pressure-lowering medication, a 
low-salt diet or ischemia results in an apparent recruitment of new renin-producing 
cells along the afferent arterioles [2], which has been proposed to represent a partial 
return to the developmental pattern of JG cell distribution. Altogether, renin-produc-
ing JG cells display many unique biological features and because of their central role 
in modulating blood pressure and fluid balance, there has been long-standing interest 
in obtaining a better understanding of their origins and biology.
Efforts to characterize JG cells have historically been hampered by two factors: 









granules and, concomitantly, their ability to proteolytically activate prorenin. As a re-
sult, attempts to immortalize both mouse and human renin-producing cells have re-
sulted in the establishment of cell lines that have lost the ability to secrete renin [3-4]. 
Second, JG cells make up only approximately 1/1000 of the cell mass of the kidney, 
making it difficult to isolate sufficient quantities of pure cells for further characteriza-
tion. As an alternative approach, Brunskill et al. [5] targeted yellow fluorescent protein 
to mouse JG cells and used fluorescence-activated cell sorting (FACS) to enrich tagged 
cells for expression analysis. The resulting study proposed a 369 gene “signature” that 
characterizes mouse JG cells, although few of these have been verified in subsequent 
studies.
In an effort to extend these studies and to determine if the genes identified in 
the mouse also characterize human renin-producing cells, we have catalogued the 
gene expression pattern of biopsies derived from 4 human renin-producing tumors, or 
reninomas. Reninomas are rare, benign tumors arising from a proliferation of JG cells 
in the kidney cortex [6-7] and are often detected due to the appearance of fulminant 
hypertension in relatively young patients (mean age under 30 years) with no obvi-
ous explanatory risk factors. RNA sequencing (RNA-Seq) revealed a set of 54 highly 
expressed genes that are common to all four tumors and another 30 expressed in 3 
of the 4 biopsies tested. In situ hybridization of mouse kidney sections subsequently 
confirmed JG cell expression of 44 of these genes, the vast majority of which  have 
not previously been reported to be expressed in JG cells. Finally, hypothesizing that 
the highly expressed reninoma genes affect renin-synthesizing capacity, we selected 
10 ligands (based on known relevance for blood pressure and kidney disease) and 
studied their effects on (pro)renin release by As4.1 cells. These cells are derived from 
a transgene-induced mouse kidney tumor, and do not store renin. They may thus be 
considered as de-differentiated JG cells which have lost their capacity to secrete lyso-
somes. Consequently, As4.1 cells might serve as a model to study the effect of renino-
ma-specific ligands on JG cell plasticity. Results revealed an unexpected suppressant 
role for platelet-derived growth factor B (PDGFB). 
METHODS
Human and mouse studies
Total RNA was isolated using Trizol (Invitrogen) from four  reninomas surgically 
obtained from four anonymous patients (Paris1, Paris2, Montreal, Rotterdam), and un-
derwent RNA-sequencing analysis using the HiSeq2000 (Illumina). The top 100 most 
up-regulated genes presented in all four, and at least in three out of four reninomas 
were submitted to immunofluorescence and fluorescent in situ hybridization (iFISH) 
in order to analyze their expression in the juxtaglomerular apparatus of kidney mice 
under different situations (5 day old, 10-12 week old and 10-12 week old treated with 
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captopril for 7 days). For further details, see the Methods section in the online-only 
Data Supplement.
Cell culture studies
Human Embryonic Kidney (HEK) 293 cells were transfected with plasmids en-
coding ligands selected from the transcriptome analysis on four reninomas. The con-
ditioned medium derived from these cells was used to study the effect of these ligands 
on (pro)renin-synthesizing As4.1 cells. For further details, see the Methods section in 
the online-only Data Supplement.
Statistical analysis
Results are expressed as mean±SEM. Data were analyzed for normal distribu-
tion using a Shapiro-Wilk’s test (P>0.05). Differences were tested using one-way or 
two-way ANOVA, followed by Holm-Sidak’s or Dunnett’s multiple comparison test. 
P<0.05 was considered significant. 
RESULTS
Deep sequencing of RNA (RNA-Seq) was performed on three biopsies of a first 
reninoma from Paris (Par1B1-B3), one biopsy from a reninoma from Montréal (Mon), 
two biopsies from a reninoma from Rotterdam (RotB1, B2), and a second reninoma 
from Paris (Par2) along with a biopsy from adjacent supposedly normal tissue from the 
same patient (Par2N) (Table S1). We obtained from 45-100 million reads per sample 
(Table 1) with comparable overall sample quality (Figure S1). Remarkably, the Frag-
ments Per Kilobase of transcript per Million (FPKM) mapped reads values for renin 
were quite similar in the four tumor samples and, in each tumor, renin was expressed 
at 15-41 times the level of the next most abundant transcript, confirming the diagnosis 
of bona fide reninomas (Table 2). 
Results obtained from the three independently analyzed biopsies of the Paris1 
reninoma demonstrated an inter-sample Spearman correlation of >0.98 (Figure S2, 
red outlines) and similar results were obtained with the two biopsies of the reninoma 
from Rotterdam (Figure S2, green outlines) suggesting that the sample preparation 
and results obtained were reliable and reproducible. In the one case in which we had 
biopsies of both tumor and adjacent tissue from a single patient (Paris 2), there was 
a 217-fold increase in the number of renin reads in the reninoma versus the “normal” 
sample (Table 2) although the samples overall were very highly correlated (0.92 for 
all genes; see Figure S2, blue outlines). By limiting the gene set analyzed in all the 
samples to those that were expressed at least 4-fold higher in the reninoma versus the 
“normal” biopsies for Paris 2, we reduced the gene set to just over 1000 (Table S2) and 
this resulted in the removal of low reads (which are commonly unreliable) and many 









100 most-expressed genes in each biopsy (Table S3). Re-calculation of the Spearman 
correlation using these highly expressed genes revealed a higher discrimination be-
tween samples (Figure S3). Although the repeat biopsies continued to exhibit a cor-
relation >0.98, the correlation between the reninomas varied between a low of 0.46 
(Par1 versus Par2) and a high of 0.74 (RotB1 and Par2). Surprisingly, the highest cor-
relation is between the Par2 and Par2N samples (0.81, Figure S3), raising the possibility 
that the supposedly normal sample from this patient contains some reninoma. A Venn 
diagram reveals that 54 of the 100 most expressed genes were common to all 4 reni-
nomas (Table S3 and Figure S4) and another 30 genes were highly expressed in 3 out 
of 4 of the tumors analyzed. Functional annotation clustering analysis (DAVID) did not 
reveal any statistically significant correlation for cellular function using the genes most 
commonly expressed in the reninomas (data not shown). 
Table 1. Quality control of sequenced reads
Sample
Number of reads 
before trimming






Par1B1 88058080 83611860 94.95 0.811
Par1B2 88713782 84187709 94.90 0.803
Par1B3 74683086 71782557 96.12 0.813
Mon 76131363 73212125 96.17 0.760
Rot1B1 117331030 109192033 93.06 0.753
Rot1B2 95468148 88616034 92.82 0.766
Par2 55053372 47536436 86.35 0.766
Par2N 117480551 101148769 86.10 0.647
Table 2. Ratio of the number of renin reads (FPKM) obtained in the various biopsies 
versus those for the next most abundant transcript. Also shown is the ratio of renin 
reads obtained between the putative tumor and normal adjacent tissue (Par2N) 
biopsies for the Par2 samples. Data are drawn from Table S1.
Sample Par1 (ave.) Mon Rot (ave.) Par2 Par2N Par2/Par2N
Ren FPKM 74372 110034 110062 117805 541 217
2nd transcript 
(FPKM)
GNAS (2218) GNAS (2652) KISS1 (6830) KISS1 (8110)
Ratio 33.53 41.49 16.11 14.53
To test if these reninoma-enriched genes were also expressed in JG cells, we 
performed iFISH for 71 of the above 84 common reninoma transcripts (excluding, 
among others, genes that have no mouse equivalent) in kidney sections from C57bl/6 
mice using the equivalent mouse probes (Table 3 and Figure S5). As expected, com-
bined in situ hybridization and immunofluorescence for renin reveals perfect co-local-
ization in the JG cells of adult mice (Figure 1A-1D). Furthermore, treatment of the mice 
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with captopril for one week resulted in the expected recruitment of JG cells along the 
afferent arterioles (Figure 1E), while co-localization was also observed throughout the 
maturing arterioles of 5 day-old mice (Figure 1F). These results confirm the validity of 
this approach to assess the co-localization of the transcripts from the reninoma in the 
mouse JG cells. 
Figure 1. iFISH for renin in mouse kidney. Where possible, glomeruli are outlined in red and vessels 
in light blue. (A) Immunofluorescence for renin in adult mouse kidney is shown in blue; (B) In situ 
hybridization for renin in the same section is shown in yellow; (C) merged image from panels a 
and b, including phase contrast microscopy showing that renin is expressed at the base of the 
glomeruli as expected; (D) iFISH overlay for renin in kidneys from adult; (E) adult mouse treated for 
one week with captopril, and (F) 5 day-old mouse. Original magnification X 20. Scale bar=50µm.
In order to obtain a semi-quantitative comparison of gene expression levels in 
renin-producing cells, all confocal microscopy images were taken using the same pa-
rameters and a ranking from 0 (for no expression observed) to 4 (highly expressed) was 
assigned for each gene under each condition tested (Table 3). Among the 71 genes 
tested, 44 genes are expressed in both reninomas and mouse JG cells. Twenty-four 
of these were detected in all three conditions (5 day-old, adult and adult treated with 
captopril kidneys) while the remainder showed preferential expression in one or more 
of the conditions (Figure S5 and Table 3). Functional annotation clustering analysis 
using the 44 genes expressed in both the reninomas and mouse JG cells identified 









Table 3. Summary of the iFISH analysis on mouse kidney for the genes most highly 
expressed in the reninomas. The genes found to express in renin-producing cells (RPC) 
are listed in their order of expression in the reninomas from highest to lowest (see 
Table S1) and their relative expression in each sample is estimated on a scale of 0 (no 
detectable expression) to 4 (highest expression), based upon the data in Figure S5. 
*Described as part of a 369 gene list that makes up a renin-producing cell signature, 
according to Brunskill et al.5; #Reported as reninoma marker. Of the genes confirmed 
by iFISH, 36 have not been reported before in relationship to renin-producing cells.
Gene symbol Gene ID
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From the top 100 highly expressed genes, focusing on blood pressure regula-
tion and renal disease, we selected 10 genes coding for ligands (FSTL1, IGF2, LGALS1, 
MDK, MFGE8, NPPC, PDGFB, SPARC, SPARCL1, WFDC2) in order to investigate their 
potential role in JG recruitment. The corresponding mouse cDNAs were cloned with 
a c-myc epitope and transfected into HEK293 cells to obtain high concentrations of 
these ligands in the supernatant of the culture medium. WB experiments confirmed 
the presence of the proteins of each of the transfected genes in the HEK293 cell me-
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dium at 48 hours after transfection (Figure S6). Since all ligands were tagged with a 
c-myc epitope, the same primary antibody could be used. 
After adding the 48-hour conditioned HEK293 medium (containing the highest 
level of the desired protein) to (pro)renin-producing As4.1 cells for 2 days, we studied 
As4.1 cell morphology and quantified (pro)renin in the medium. Only PDGFB altered 
As4.1 cell morphology, in that the cells after exposure to this ligand displayed a more 
elongated densely packed and aligned shape (Figure S7). Moreover, PDGFB also in-
duced parallel decreases in the medium and cellular (pro)renin levels, by 64±5% and 
53±10%, respectively (n=11), although only the former was significant (P=0.03; Figure 
2A). Under control conditions, the medium contained predominantly (>95%) prorenin. 
In contrast, the cell lysate contained renin only, at levels corresponding to <1% of the 
total amount of renin+prorenin in the medium. qPCR experiments revealed that the 
reduction in (pro)renin also occurred at the expression level, decreasing its level by 
84±5% (P=0.005, n=5; Figure 2A). Furthermore, when applying commercially obtained 
PDGFB directly to As4.1 cells, it lowered (pro)renin concentration-dependently (Figure 
2B), and from these data, it could be estimated that the PDGFB level in the conditioned 
HEK293 medium was >100 ng/mL. MTT assays confirmed that the effect of PDGFB was 
not due to a reduction in cell viability (Figure 2B). Moreover, PDGFB did not affect total 
protein content, suggesting that its effect was also not due to a decrease in cell num-
ber (data not shown).   
Finally, we evaluated the effect of PDGFB-containing HEK293 medium on 
the expression of markers that illustrate the occurrence of a smooth muscle, endo-
crine and/or immunological phenotype, i.e., aldo-keto reductase family 1, member 
B7 (Akr1b7), a-smooth muscle actin (Acta2), interleukin-6 (IL-6), and Recombination 
signal binding protein for immunoglobulin kappa j (Rbpj). Figure 2C illustrates that 
PDGFB upregulated IL-6 (P<0.0001, n=4), and downregulated Acta2 (P=0.01, n=6) in 
As4.1 cells. Non-significant increases in Akr1b7 (P=0.06, n=4) and Rbpj (P=0.06, n=5) 
expression were also observed. 
DISCUSSION
The aim of this study was to gain insight into human JG cell biology. Given their 
rapid de-differentiation in culture, such knowledge is currently lacking. Instead, infor-
mation on renin synthesis is largely derived from renin-producing tumor-derived cell 
lines, like As4.1 (mouse), Calu-6 (human) and human mastocytoma cells (HMC-1). In an 
attempt to catalogue the genes expressed in JG cells, Brunskill et al. [5] used a f luo-
rescent repor ter mouse model, in which they have used cell sorting to enrich for 
gene-tagged renin-expressing cells in the mouse kidney. Comparison of gene expres-
sion arrays from the sorted cells versus the whole kidney led to the identification of 
369 core genes whose expression was proposed to constitute a “gene signature” for 
the mouse JG cell. In the current study, we have used direct RNA sequencing (RNA-
Seq) of human reninomas to independently quantify gene expression levels in each 
Figure 2. A) Total renin (i.e., renin + prorenin) levels in the medium, and renin levels in the cell 
lysate obtained from As4.1 cells incubated for 48 hours with medium obtained from HEK293 
cells transfected with 10 genes expressing ligands that were upregulated in the 4 reninomas. 
Renin gene expression is also provided. Data are mean ±SEM of 5-11 experiments and have 
been expressed as a percentage of the levels in cells exposed to medium of control-transfected 
cells, i.e., cells treated with the transfection mix, but without cDNA. *P<0.01. B) Cell viability and 
total renin levels in the medium of As4.1 cells exposed to PDGFB for 24 or 48 hours. Data are 
mean ±SEM of 3 experiments and have been expressed as a percentage of the levels in cells 
not exposed to PDGFB (’vehicle’=0). *P<0.01, #P<0.05 vs. 100%. C) Aldo-keto reductase family 
1, member B7 (Akr1b7), a-smooth muscle actin (Acta2), interleukin-6 (IL-6), and recombination 
signal binding protein for immunoglobulin kappa j (Rbpj) expression in As4.1 cells incubated for 
48 hours with medium obtained from HEK293 cells transfected with 10 genes expressing ligands 
that were upregulated in the 4 reninomas. Data are mean ±SEM of 4-6 experiments and have been 
expressed as fold change versus the levels in cells exposed to medium of control-transfected cells, 









dium at 48 hours after transfection (Figure S6). Since all ligands were tagged with a 
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53±10%, respectively (n=11), although only the former was significant (P=0.03; Figure 
2A). Under control conditions, the medium contained predominantly (>95%) prorenin. 
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84±5% (P=0.005, n=5; Figure 2A). Furthermore, when applying commercially obtained 
PDGFB directly to As4.1 cells, it lowered (pro)renin concentration-dependently (Figure 
2B), and from these data, it could be estimated that the PDGFB level in the conditioned 
HEK293 medium was >100 ng/mL. MTT assays confirmed that the effect of PDGFB was 
not due to a reduction in cell viability (Figure 2B). Moreover, PDGFB did not affect total 
protein content, suggesting that its effect was also not due to a decrease in cell num-
ber (data not shown).   
Finally, we evaluated the effect of PDGFB-containing HEK293 medium on 
the expression of markers that illustrate the occurrence of a smooth muscle, endo-
crine and/or immunological phenotype, i.e., aldo-keto reductase family 1, member 
B7 (Akr1b7), a-smooth muscle actin (Acta2), interleukin-6 (IL-6), and Recombination 
signal binding protein for immunoglobulin kappa j (Rbpj). Figure 2C illustrates that 
PDGFB upregulated IL-6 (P<0.0001, n=4), and downregulated Acta2 (P=0.01, n=6) in 
As4.1 cells. Non-significant increases in Akr1b7 (P=0.06, n=4) and Rbpj (P=0.06, n=5) 
expression were also observed. 
DISCUSSION
The aim of this study was to gain insight into human JG cell biology. Given their 
rapid de-differentiation in culture, such knowledge is currently lacking. Instead, infor-
mation on renin synthesis is largely derived from renin-producing tumor-derived cell 
lines, like As4.1 (mouse), Calu-6 (human) and human mastocytoma cells (HMC-1). In an 
attempt to catalogue the genes expressed in JG cells, Brunskill et al. [5] used a f luo-
rescent repor ter mouse model, in which they have used cell sorting to enrich for 
gene-tagged renin-expressing cells in the mouse kidney. Comparison of gene expres-
sion arrays from the sorted cells versus the whole kidney led to the identification of 
369 core genes whose expression was proposed to constitute a “gene signature” for 
the mouse JG cell. In the current study, we have used direct RNA sequencing (RNA-
Seq) of human reninomas to independently quantify gene expression levels in each 
Figure 2. A) Total renin (i.e., renin + prorenin) levels in the medium, and renin levels in the cell 
lysate obtained from As4.1 cells incubated for 48 hours with medium obtained from HEK293 
cells transfected with 10 genes expressing ligands that were upregulated in the 4 reninomas. 
Renin gene expression is also provided. Data are mean ±SEM of 5-11 experiments and have 
been expressed as a percentage of the levels in cells exposed to medium of control-transfected 
cells, i.e., cells treated with the transfection mix, but without cDNA. *P<0.01. B) Cell viability and 
total renin levels in the medium of As4.1 cells exposed to PDGFB for 24 or 48 hours. Data are 
mean ±SEM of 3 experiments and have been expressed as a percentage of the levels in cells 
not exposed to PDGFB (’vehicle’=0). *P<0.01, #P<0.05 vs. 100%. C) Aldo-keto reductase family 
1, member B7 (Akr1b7), a-smooth muscle actin (Acta2), interleukin-6 (IL-6), and recombination 
signal binding protein for immunoglobulin kappa j (Rbpj) expression in As4.1 cells incubated for 
48 hours with medium obtained from HEK293 cells transfected with 10 genes expressing ligands 
that were upregulated in the 4 reninomas. Data are mean ±SEM of 4-6 experiments and have been 
expressed as fold change versus the levels in cells exposed to medium of control-transfected cells, 
i.e., cells treated with the transfection mix, but without cDNA (‘vehicle’). *P<0.01, #P<0.05 vs. 1.0. 
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of the biopsies we obtained, and to test for correlation of the gene expression pat-
terns between mouse and human renin-expressing cells. This approach has the addi-
tional advantage that a control tissue to which expression can be compared was not 
required. This was an important consideration since our samples were derived from 
frozen pathology specimens, and only one of them had a corresponding biopsy of 
adjacent, presumed non-tumor, tissue. The high reproducibility and sequence “depth” 
achieved confirm that this approach is valid, robust and applicable to archival samples 
and the comparison of the reninoma transcriptomes allowed us to derive a gene ex-
pression “fingerprint” for the tumors. In addition, the high expression of renin, CD34, 
and vimentin, all of which have been previously reported as markers of reninomas, 
[7-8] confirms the diagnosis of bona fide reninoma in all of the tumors. 
At least 3 of the 4 reninomas expressed genes at relatively high levels that were 
also reported to be highly expressed in mouse renin-expressing cells [5] including, in 
addition to renin, RGS5, CRIP1, and ATP1B2. Conversely, a number of the most highly 
expressed transcripts previously identified in the mouse JG cell preparations were not 
detected in the 100 most-expressed genes in the reninomas including Syne2, Plac9, 
Myh11, Jph2, Myo18, Akr1b7 and Mgp. Interestingly, Akr1b7, a member of the alpha-ke-
to reductase gene family was previously found to be highly enriched in mouse JG cell 
preparations and to serve as a specific marker for JG cells in the mouse kidney [5]. Even 
though Akr1b7 does not have a homologue in humans, its closest human analogues, 
AKR1B10 and AKR1B15, are not expressed at detectable levels in the reninomas (data 
not shown). Since more recent results have shown that targeted deletion of Akr1b7 in 
mouse JG cells does not affect renin production [9] it is possible that the expression of 
Akr1b7 in mouse JG cells is unrelated to renin synthesis.  
Indeed, of the extended list of 369 core genes previously reported to be en-
riched in the mouse renin cell preparations [5] only 8 were among the 84 genes ex-
pressed in at least 3 of the 4 reninomas (Table 3 and Table S3). Although the exact 
reason for these differences is unclear, they could be due to several factors. First, some 
of the highly-expressed transcripts in the reninomas might be related to the tumoral 
transformation of the renin-producing cells. For example, the expression of neither 
CD34, a commonly reported marker of reninomas and myelo-lymphopoetic precur-
sors, nor insulin-like growth factor 2 (IGF2) was detected in the mouse JG cells. IGF2 
also did not affect (pro)renin release by As4.1 cells. Alternatively, the differences could 
be due to the fact that in both the current study and that of Brunskill et al. [5], the gene 
expression patterns were obtained from impure populations of renin-producing cells 
and could reflect expression of a gene in a contaminating non-JG cell. Finally, they 
could reflect true differences between mouse and humans. 
To overcome some of these limitations, we used iFISH to test whether the com-
monly expressed genes in the reninomas were also expressed in mouse JG cells (Figure 
S5). Even though the sensitivity of this analysis is limited by the level of expression 
of the candidate genes, it nevertheless confirmed that 44 of the gene transcripts ex-
pressed in the reninomas were also detected in mouse JG cells (Table 3) and thereby 









Previous studies have reported that JG cells express contractile proteins, are 
related to pericytes [5] and, like pericytes, are derived from FoxD1-expressing lineages 
[10]. Simultaneously, renal CD44(+) mesenchymal stem cell-like cells, whose differen-
tiation is triggered by LXR stimulation [11] have been suggested to differentiate into 
JG-like renin-expressing cells [12]. The current analysis confirmed the expression of a 
number of contractile proteins in both reninomas and JG cells, including myosin light 
chain 9 (MYL9), tropomyosin 2 (TPM2), transgelin (TAGLN), myocyte enhancer factor 
2C (MEF2C), caldesmon (CALD1) and very low levels of ACTA2, as well as some pericyte 
markers including RGS5 and osteonectin (SPARC). We also confirmed the expression of 
vimentin (VIM), a marker of mesenchyme-derived cells, in both the reninomas and JG 
cells, but did not detect expression of either LXR receptor or CD44 in the tumors.  
Our data also call into question the model that “recruited” JG cells (e.g., after 
captopril treatment) represent a return to the embryonic stage of renin-producing 
cells. The ACTA2 gene codes for a-smooth muscle actin, a marker for smooth muscle 
cells. Consistent with what has been previously reported [13] there is a demarcation in 
Acta2 expression with the expected higher expression in smooth muscle cells of the 
afferent arteriole and very low expression in adjacent JG cells of adult mice (Figure 3A). 
This demarcation persists after recruitment of new JG cells following captopril treat-
ment (Figure 3B). In contrast, there appear to be 2 populations of renin-expressing 
cells in the developing kidney: one population that exists in clusters similar to the JG 
apparatus in adult kidney (Figure 3C, arrow) and which express only very low levels 
of ACTA2 and others which line the vessels of the developing kidney and exhibit sig-
nificant overlap of renin staining and ACTA2 expression (Figure 3C, light blue outline). 
Other genes whose expression was detected almost exclusively in renin-producing 
cells of the developing kidney include A2m, Slit3 and Cxcl12. Conversely, a number 
of genes appeared to be preferentially expressed in the JG cells of adult control and 
captopril-treated mice including Ptp4a3, C4a, Tinagl1, Lbh, Mdk, Bgn and Crip1. Taken 
together, these results suggest that JG recruitment does not simply involve a return to 
the embryonic renin-producing cell, but may rather reflect differentiation of smooth 
muscle to either an intermediate or alternative phenotype.
KISS1, which codes for a metastasis suppressor and is the second to third most 
abundant transcript in each of the four of the reninomas (Table 3), also presents a 
major difference in expression in the reninomas and mouse kidney. The KISS1 gene 
is located immediately adjacent to the renin gene on chromosome 1 in both mice 
and humans (http://www.ncbi.nlm.nih.gov/gene/3814). When large chromosomal 
fragments containing both genes are used to generate transgenic mice, coordinate 
expression of renin and KISS1 is detected in brain, kidney, lung and placenta [14]. While 
we detected some expression of Kiss1 in the JG cells of captopril-treated mice (Figure 
S5), we did not detect its expression in adult mouse JG cells, raising the possibility that 
the neighboring Kiss1 gene is expressed only in conditions of very high renin gene 
expression. Whether it explains the fact that intra-renal reninomas rarely metastasize 
is currently unknown.
Also among the most highly expressed genes in all 4 reninomas is DBNDD2 
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(Table S3), a paralog of the gene DTNBP1, which is a component of the BLOC-1 com-
plex that is required for normal biogenesis of lysosome-related organelles (LRO), such 
as platelet dense granules and melanosomes. Thus, DBNDD2 might be an interesting 
candidate to explain the high content of LROs found in the JG cells. 
Figure 3. iFISH showing renin immunofluorescence in blue and in situ hybridization 
for Acta2 or Pdgfrβ in yellow in kidneys from adult (A, D), captopril-treated (B, 
E), 5 day-old (C, F) mice. Note the existence of 2 types of renin-producing cells in 
the 5 day-old mouse: those that co-express Acta2 (outlined in the vessel in light 
blue) and those that don’t (arrow). Original magnification X 40. Scale bar=50µm.
A number of ligands and receptors were also found to be highly expressed in 
the reninomas and in mouse renin-producing cells, some of which might play a role 
in either the maintenance of the JG cell phenotype or in JG cell recruitment. Of partic-
ular interest is the high level of expression of the Notch3 receptor and PDGF receptor 
ß (PDGFRß) in the reninomas and JG cells. Indeed, RBPJ, the main effector involved 
in Notch receptor signaling, activates the myo-endocrine program of the JG cell, and 
conditional deletion of Rbpj in renin-producing cells results in a dramatic decrease in 
the number of JG cells seen in adult mice [15]. Yet, in humans mutations in NOTCH3 
have been identified as the underlying cause of cerebral autosomal dominant arteri-
opathy with subcortical infarcts and leukoencephalopathy (CADASIL), with no known 
effects on renin. In the current study we observed that PDGFB suppressed (pro)renin 









of Acta2 and upregulation of IL-6 suggests an As4.1 phenotype change from myo-en-
docrine to inflammatory. IL-6 upregulation by PDGFB is well-known, and occurs in a 
RBPJ-independent manner [16]. No significant alterations were observed in Akr1b7 
and Rbpj, nor did PDGFB affect cell viability. Classically, endothelium-derived PDG-
FB recruits pericytes and promotes VSMC proliferation [17]. Importantly, pericytes in 
the human kidney were recently reported to produce renin [18]. Hypoxia transforms 
renin-producing cells into erythropoietin-producing cells, [19] and erythropoietin-ex-
pressing cells are assumed to be derived from capillary pericytes [20]. Finally, follow-
ing severe mesangial injury, renin-positive precursor cells moved into intraglomerular 
sites and differentiated into (renin-negative), PDGFRß-expressing mesangial cells [21]. 
As shown in Figure 3 (panels D-F), PDGFRß modestly overlapped with renin in kidneys 
of adult, young, and captopril-treated adult mice, in addition to its well-known expres-
sion in interstitial cells. Moreover, Rider et al. observed that renin cells in the zebrafish 
kidney express both Acta2 and Pdgfrβ [22]. Given the well-known role of endothelial 
PDGFB as a facilitator of mesangial cell proliferation and migration, an additional effect 
of PDGFB might now be suppression of renin expression. Here it should be mentioned 
that neither conditional deletion of the PDGFRß in renin-producing cells nor deletion 
of endothelial PDGFB production affected the normal development of renal renin-ex-
pressing cells [23]. This may not be too surprising, given the fact that PDGFB actually is 
a negative regulator of renin expression, possibly coming into play only under patho-
logical conditions.
Besides the high level of PDGFRß expression in the reninomas and the JG cells, 
both also express the genes for SPARC, SPARCL1 (SPARC-like 1 or hevin) and MFGE8 
(lactadherin) at relatively high levels. It has been reported that SPARC can both pre-
vent the binding of PDGF to its receptor [24] and potentiate its profibrotic effects [23], 
while lactadherin potentiates PDGFRß signaling [25]. This raises the possibility that a 
more complex interplay between SPARC, SPARCL1, MFGE8 and PDGF regulates either 
the recruitment or other physiological responses of JG cells in their natural setting. 
In agreement with this concept, the current study revealed no effect of either SPARC, 
SPARCL1 or MGE8 alone on (pro)renin synthesis by As4.1 cells. Additionally,  ligands 
that are known to be involved in blood pressure regulation (NPPC, or natriuretic pep-
tide precursor C), diabetic nephropathy (LGALS1 or galectin-1) [26], nephrogenesis 
(MDK or midkine) [27], renal fibrosis (WFDC2, or WAP four-disulfide core domain pro-
tein 2) [28], and renal injury prevention (FSTL1, or follistatin-related protein 1) [29] also 
did not directly affect (pro)renin synthesis by As4.1 cells. 
Somewhat surprisingly, no proteases were included in the 100 most expressed 
genes in the reninomas (Table S3) where we might have expected to find one or more 
candidate prorenin processing enzymes (PPE) necessary for proteolytic activation of 
the renin secreted by these tumors. However, examination of the gene lists before sub-
traction of the genes expressed in the Par2N “normal” biopsy (Table S1) reveals that the 
rank of Cathepsin B (CTSB) expression varies from the 8th (Par1B1) to the 78th (Par2) po-
sition in the reninomas, although these expression levels did not appear to correlate 
with the apparent renin expression levels in each sample (not shown). However, be-
Chapter 2
48
cause CTSB was only expressed 1.1-fold more in the Par2 reninoma than in the Par2N 
control kidney biopsy, it was eliminated from our gene list. Nevertheless, because 
CTSB has been co-localized with renin in JG cells secretory granules [30] and shown 
to accurately process human prorenin in vitro [31], it is quite possible that it fulfills the 
role of the PPE in the reninomas, even though it is a ubiquitously distributed protease. 
This analysis also reveals one of the potential shortcomings of our approach since by 
focusing on genes whose expression was consistently enriched in tumor biopsies we 
may have eliminated consideration of genes that play an important functional role in 
the biology of the JG cell, but whose expression is more widely distributed.
The present study is the first to use a reninoma transcriptome analysis as an 
approach to understand human JG cell biology. It has yielded multiple new candidates 
that might play a role in the developmental plasticity of these cells and, among them, 
raises the PDGFB-PDGFRβ signaling pathway as a promising novel pathway that con-
trols renin-expressing cells.  
PERSPECTIVES
By comparing the transcriptomes of 4 reninomas and subsequently mapping 
the expression patterns of the most highly expressed genes in mouse kidney during 
development, adulthood and following renin-producing cell recruitment in response 
ACE inhibition, we have confirmed the expression of 36 new genes (Table 3) in this 
unique cell type. As a result, we propose the PDGFB-PDGFRβ signaling pathway as a 
promising novel pathway that controls the developmental plasticity of JG cells. 
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Due to the presence of the blood-brain barrier, brain RAS activity should depend on 
local (pro)renin synthesis. Indeed, an intracellular form of renin has been described in 
the brain, but whether it displays angiotensin I-generating activity (AGA) is unknown. 
Here, we quantified brain (pro)renin, before and after buffer perfusion of the brain, in 
wild-type mice, renin knockout mice, DOCA-salt-treated mice, and angiotensin II-in-
fused mice. Brain regions were homogenized and incubated with excess angioten-
sinogen to detect AGA, before and after prorenin activation, using a renin inhibitor 
to correct for non-renin-mediated AGA. Renin-dependent AGA was readily detectable 
in brain regions, the highest AGA being present in brainstem (>thalamus=cerebel-
lum=striatum=midbrain>hippocampuscortex). Brain AGA increased marginally after 
prorenin activation, suggesting that brain prorenin is low. Buffer perfusion reduced 
AGA in all brain areas by >60%. Plasma renin (per mL) was 40-800x higher than brain 
renin (per g). Renin was undetectable in plasma and brain of renin knockout mice. DO-
CA-salt and angiotensin II suppressed plasma renin and brain renin in parallel, without 
upregulating brain prorenin. Finally, angiotensin I was undetectable in brains of spon-
taneously hypertensive rats, while their brain/plasma angiotensin II concentration 
ratio decreased by 80% after AT1 receptor blockade. In conclusion, brain renin levels 
(per g) correspond with the amount of renin present in 1-20 mL plasma. Brain renin dis-
appears after buffer perfusion, and varies in association with plasma renin. This indi-
cates that brain renin represents trapped plasma renin. Brain angiotensin II represents 
angiotensin II taken up from blood rather than locally synthesized angiotensin II. 
INTRODUCTION 
Since the discovery of renin in the brain nearly 50 years ago [1], numerous stud-
ies have proposed that a so-called brain renin-angiotensin system (RAS) exists. Given 
the presence of the blood-brain barrier, brain RAS activity should depend on the local 
synthesis of renin or prorenin (together denoted as (pro)renin) in the brain rather than 
uptake from blood. In support of this concept, an intracellular, non-secreted form of 
renin (icREN) has been shown to occur exclusively in the brain. This renin isoform is 
derived from an alternative transcript of the renin gene, lacking the signal peptide and 
part of the prosegment [2-3]. To what degree this truncated prorenin truly generates 
angiotensin (Ang) I remains elusive. Lee-Kirsch et al. detected low Ang I-generating ac-
tivity (AGA) levels in cell lysates of AtT20 cells transfected with icREN during incubation 
with excess angiotensinogen, but failed to demonstrate to what degree this AGA was 
renin-mediated (e.g., by making use of a renin inhibitor). Peters et al. showed increased 
AGA in cardiac homogenates of transgenic rats overexpressing icREN and were able to 
block this with the renin inhibitor CH732 [4]. Yet, unexpectedly, the AGA increase was 
observed only after prosegment removal with trypsin, in disagreement with the fact 
that truncated prorenin does not require prosegment removal to display activity [5]. 
Moreover, icREN overexpression in the heart, if anything, resulted in effects that were 









DOCA-salt treatment is widely believed to stimulate brain RAS activity. Confus-
ingly, it lowers icREN expression, but increases the expression of the classical, secret-
ed form of renin in brain tissue (sREN) [7], possibly because, icREN, via an unknown 
mechanism, inhibits sREN expression [8]. Li et al. proposed that DOCA-salt selectively 
increases brain prorenin, which, in the absence of a prosegment-cleaving enzyme in 
the brain, requires interaction with the (pro)renin receptor to allow Ang I generation 
locally [9-10]. The underlying assumption of this concept is that prorenin binding to 
the (pro)renin receptor results in a conformational change in the prorenin molecule, 
allowing it to display enzymatic activity without prosegment cleavage [11]. Yet, the 
low (nanomolar) affinity of the (pro)renin receptor implies that very high prorenin lev-
els are required for receptor binding [11], for which there currently is no evidence [10].
Given these uncertainties, in the present study we set out to re-evaluate the 
occurrence of (pro)renin in the brain. We quantified brain (pro)renin in a wide variety 
of brain regions, derived from control mice, mice exposed to DOCA-salt or Ang II, and 
renin-deficient mice. Under all conditions, a comparison was made with plasma (pro)
renin, and the renin inhibitor aliskiren was applied in the assay to evaluate whether 
AGA was truly renin-mediated. Mice were studied given the fact that their (pro)renin 
levels are several orders of magnitude higher than those in humans or rats, thereby 
facilitating the detection of renin-dependent AGA, even in areas with low (pro)renin 
levels. To obtain a more complete understanding of the brain RAS, we also quantified 
brain angiotensinogen, and we studied the changes in brain angiotensin generation 
making use of brainstem tissue obtained from control spontaneously hypertensive 
rats (SHR) and SHR treated with the Ang II type 1 (AT1) receptor blocker (ARB) olmesar-
tan or the ACE inhibitor lisinopril for 4 weeks. 
METHODS
Mouse and rat studies
Renin, prorenin and angiotensinogen were measured in plasma and brain re-
gions (cerebellum, brainstem, cortex, hippocampus, midbrain, striatum and thalamus) 
obtained from wild-type (WT) mice, mice treated with deoxycorticosterone acetate 
(DOCA)-salt or angiotensin II, and renin-deficient mice (Ren1c-/-), either without and 
with transcardial perfusion with PBS to wash away blood from the brain vasculature. 
Renin expression in brain tissue was also explored by using Ingenuity Pathway Analy-
sis (IPA), and angiotensinogen synthesis was additionally studied in rat primary corti-
cal astrocytes. Angiotensins were measured in plasma and brainstem tissue obtained 
from SHR treated with vehicle, lisinopril or olmesartan. For further details, see the 




Data are expressed as mean±SEM. Univariate linear associations between 
plasma and brain renin levels were assessed by calculation of Pearson’s coefficient of 
correlation. Differences between groups were evaluated by Student’s t-test or ANO-
VA, and corrected for multiple testing by post-hoc Bonferroni analysis when needed. 
P<0.05 was considered significant.
RESULTS
Aliskiren inhibits angiotensin I-generating activity (AGA) in the mouse brain
Aliskiren identically inhibited AGA in mouse plasma (n=2), mouse kidney ho-
mogenate (n=2) and mouse brain homogenate (n=3) (Figure 1). Its IC50 was in the 
nanomolar range, as has been reported before for mouse renin [12-13]. These data 
suggest that AGA in mouse brain homogenates is due to renin. All subsequent AGA 
measurements were performed both in the absence and presence of 10 mmol/L ali-
skiren in order to correct for non-renin (i.e., non-aliskiren-inhibitable) AGA.   
Buffer perfusion reduces mouse brain renin by >60%
Renin-dependent (i.e., aliskiren-inhibitable) AGA was readily detectable in brain 
regions, the highest AGA being present in brainstem (>thalamus =cerebellum =stria-
tum =midbrain >hippocampus =cortex) (Figure 2, n=5/group). AGA increased in each 
individual brain region after prorenin activation, but only when analyzing all brain re-
gions together by multivariate ANOVA did this increase reach significance (P<0.05). 
Applying the prorenin activation procedure to 3 mouse brain homogenates (cortex, 
Figure 1. Concentration-
dependent inhibition of 
angiotensin I-generating 
activity (AGA) by aliskiren in 
mouse plasma (n=2), mouse 
kidney homogenate (n=2) 
and mouse brain homogenate 
(n=3, representing pooled 
brainstem, cortex and 
midbrain regions, respectively, 









midbrain and brainstem, respectively) to which recombinant human prorenin had 
been added yielded values in a renin IRMA (211±12 pg/mL) that were similar to those 
when activating the same amount of recombinant human prorenin in buffer with ali-
skiren [14] (169±6 pg/mL). This confirms that our prorenin activation procedure was 
appropriate. PBS perfusion of the mouse brain reduced AGA in all brain areas by >60% 
(Figure 2; P<0.01), and diminished the percentage of AGA that could be blocked by 
aliskiren (Table S2). These data suggest that blood removal predominantly washes 
away renin, but not non-renin enzymes that are also capable of reacting with angio-
tensinogen. Plasma renin (expressed per mL plasma) was 40-800x higher than brain 
renin (expressed per g tissue), and, as expected, identical in mice that were exposed to 
buffer perfusion. Plasma prorenin levels were of the same order of magnitude as plas-
ma renin levels, as demonstrated earlier in mice [15]. 
Comparable reductions in brain and plasma (pro)renin after DOCA-salt treat-
ment, angiotensin II infusion and renin-deficiency
Figure 2. Renin and total renin (=renin + prorenin) levels in plasma and brain regions 
of mice before and after buffer perfusion (wash) of the brain. Data are mean±SEM of 
n=5. Multivariate ANOVA showed that total renin levels were higher than renin levels 
(P<0.05), and that buffer perfusion reduced renin by >60% in all regions (P<0.01). 
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DOCA-salt (n=6) and Ang II (n=7) suppressed plasma renin versus WT (n=6), and 
parallel decreases were observed for brainstem, midbrain and cortex renin (Figure 3), 
although significance was not reached in all cases. Nevertheless, brain renin levels (ex-
pressed per g tissue) correlated significantly with plasma renin levels (expressed per 
mL plasma) in all 3 brain regions (Figure 4). The different slopes may reflect the differ-
ent blood content of each brain region. Plasma prorenin levels were comparable to 
plasma renin levels, and prorenin activation in brain regions non-significantly in-
creased brain AGA. Plasma renin and prorenin were undetectable in Ren1c-/- mice 
(n=4), and renin (i.e., aliskiren-inhibitable AGA) was also undetectable in the 3 brain 
regions obtained from Ren1c-/- mice. However, low levels of aliskiren-inhibitable AGA 
were present in brainstem (1 out of 4) midbrain (3 out of 4) and cortex (2 out of 4) after 
prorenin activation in the Ren1c-/- mice. Since this cannot represent prorenin, these 
data imply that our prorenin activation procedure occasionally activated a renin-like 
enzyme, capable of reacting with angiotensinogen, the activity of which can be 
blocked by 10 mmol/L aliskiren. 
Figure 3. Renin and total renin (=renin + prorenin) levels in plasma and brain regions of untreated 
mice (WT), mice treated with DOCA-salt, mice infused with Ang II, and Ren1c-/- mice. Data are 
mean±SEM of n=4-7. Differences in renin levels were assessed by one-way ANOVA, followed by 









Renin expression in the brain
Renin (secreted + intracellular), sREN or icREN mRNA expression levels were un-
Figure 4. Relationship 
between renin in plasma 
and renin in 3 different brain 
regions in untreated mice 
(WT, n=6), mice treated with 
DOCA-salt (n=6) and mice 
infused with Ang II (n=7). 
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detectable in all brain regions in WT, DOCA-salt-treated and Ang II-infused mice. Prim-
er specificity for renin (secreted + intracellular) and sREN was validated by measuring 
renal renin expression in Ren1c-/- mice (Figure S1B). In the IPA tissue expression data 
sets, renin expression was found in cerebellum, hypothalamus and pituitary, but only 
in 3 out of 9 different datasets examined (data not shown). 
Despite angiotensinogen expression, angiotensinogen protein is undetectable 
in mouse brain and rat astrocytes
Mouse plasma contained detectable levels of angiotensinogen (28±5 pmol/mL). 
Angiotensinogen mRNA expression was observed in different brain regions (Figure 
5), at Ct values of 23 (cerebellum), 22 (thalamus), 25 (hippocampus) and 27 (striatum) 
versus ≈18 in the liver. Brain expression levels changed inconsistently after DOCA-salt, 
Ang II and renin deficiency: an increase was observed in the thalamus after DOCA-salt 
(P<0.05), while decreases occurred in the cerebellum after DOCA-salt (P<0.05), and in 
the hippocampus after Ang II (P<0.05). Yet, angiotensinogen protein was undetectable 
(<1 pmol/g) in mouse cortex and brainstem (n=4 of each). Angiotensinogen was also 
undetectable in the medium of cultured rat astrocytes (<0.3 pmol/mL), cultured for 
24, 48, 72 or 96 hours (n=4 for each condition), or the accompanying cell lysates (<0.3 
pmol/mg protein). 
Angiotensins in the SHR brain with and without RAS blockade
Ang I, Ang-(1-7) and Ang-(2-8) were below detection limit in brain tissue of un-
treated SHR (n=6), while Ang II could be detected in the rat brain at levels correspond-
ing with ≈25% of the Ang II levels in blood plasma (Table S3 and Figure 6). Ang I and 
Ang-(2-8), but not Ang-(1-7), were detectable in plasma in untreated SHR. Brain Ang-
(1-7) and Ang-(2-8) remained undetectable after olmesartan (n=6) or lisinopril (n=4), 
while Ang I became detectable in the rat brain after both types of RAS blockade 
(P<0.001 for both). Since plasma Ang I increased ≈20-fold after olmesartan and lisino-
pril (P<0.001 for both), it could be calculated that, during both types of RAS blockade, 
brain Ang I levels corresponded with ≈1% of the Ang I levels in plasma. Olmesartan 
increased brain Ang II ≈5-fold (P<0.001) and plasma Ang II ≈25-fold (P<0.001), so that 
after AT1 receptor blockade the brain/plasma ratio of Ang II decreased by ≈80% 
(P<0.05). Lisinopril decreased plasma Ang II by >90% (P<0.001), and diminished brain 
Ang II to undetectable levels (P<0.001). Lisinopril also decreased plasma Ang-(2-8) to 
undetectable levels, and greatly increased plasma Ang-(1-7), while olmesartan in-
creased both plasma Ang-(2-8) and plasma Ang-(1-7). Taken together, given that brain 
Ang I levels correspond with ≈1% of the circulating Ang I levels, 10 mL plasma per g 









relative to plasma Ang II levels, are higher, suggesting either local synthesis or an ac-
tive uptake mechanism. The massive decrease in the Ang II brain/plasma ratio after 
olmesartan supports the latter.     
DISCUSSION
The present study confirms that renin-dependent AGA can be detected in virtu-
ally every region of the mouse brain. Yet, as compared to plasma, brain renin levels 
were very low, corresponding with the amount of renin in 1-25 mL blood plasma per g 
brain tissue (0.1-2.5 % (v/v)). This volume mimics the amount of blood plasma in vari-
ous brain regions determined with tritiated inulin or Evans blue dye [16-17]. Moreover, 
perfusing the brain with PBS prior to the collection of the various regions, reduced 
brain renin uniformly by >60%. Had local renin synthesis occurred in one or more spe-
Figure 5. Angiotensinogen mRNA expression in different brain regions in untreated mice (WT), mice 
treated with DOCA-salt, mice infused with Ang II, and Ren1c-/- mice. Data, presented as fold change 
over TubG2 relative to WT levels, are mean±SEM of n=3-6. Differences were assessed by one-way 
ANOVA, followed by correction for multiple testing by post-hoc Bonferroni analysis. *P<0.05 vs. WT.
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cific brain regions, the washout percentage should have been much lower in these 
regions, similar to the fact that in the kidney one cannot wash away stored renin [18-
19], while this does happen in non-renin producing organs like the heart [20]. Further-
more, DOCA-salt, like Ang II, reduced circulating renin, and, contrary to our expecta-
tions, did not increase brain prorenin. In fact, if anything, both DOCA-salt and Ang II 
lowered brain renin in parallel with plasma renin. Aliskiren-inhibitable AGA was entire-
ly absent in the brain of Ren1c-/- mice, supporting the validity of our brain renin mea-
surement. Taken together, our data do not support the presence of kidney-indepen-
dent (pro)renin synthesis in the brain, nor the concept that this occurs particularly in 
the DOCA-salt model. In fact, brain renin levels are so low that the accumulation of 
renin at brain tissue sites outside the blood compartment seems unlikely. This greatly 
differs from other organs (e.g., the heart), where renin diffuses freely into the intersti-
tium and/or binds to a receptor, thereby reaching tissue levels that are, on a gram ba-
sis, at least as high as the renin levels in blood plasma (on a mL basis) [20-22]. Clearly, 
the presence of the blood-brain barrier prevents such distribution.  
 
Prorenin activation resulted in modest AGA increases in all brain regions, and 
significance for this increase was only obtained by analyzing all regions together. Ap-
plying recombinant human prorenin to brain homogenates prior to the prorenin ac-
tivation procedure (on the basis of acid activation [22]) confirmed that this procedure 
resulted in complete prorenin activation. However, small rises in aliskiren-inhibitable 
Figure 6. Ang I and II levels in plasma and brain of SHR treated with vehicle (control), 
olmesartan or lisinopril. ND, not detectable. Data are mean±SEM of n=4-6. Differences 
were assessed by one-way ANOVA, followed by correction for multiple testing by post-









AGA were also observed in brain homogenates from Ren1c-/- mice after their exposure 
to acid. Since Ren1c-/- mouse brain tissue cannot contain prorenin, this implies that the 
brain contains a non-renin proenzyme, which is activated by acid exposure, and which 
is capable of cleaving Ang I from angiotensinogen in an aliskiren-inhibitable manner. 
A possible candidate is pro-cathepsin D. Indeed, renin inhibitors, at high micromolar 
concentrations, do inhibit cathepsin D [23]. Our difficulty to demonstrate prorenin in 
the brain is reminiscent of earlier studies in organs not synthesizing prorenin them-
selves, like the heart [22]. Obviously, blood plasma contains prorenin, and thus some 
prorenin should be detected in the blood-containing homogenates derived from such 
tissues. Yet only under conditions where circulating prorenin levels were greatly ele-
vated, like in heart failure in humans, did we reliably detect prorenin in cardiac tissue 
[24]. In mice, in contrast to humans, circulating prorenin levels are relatively low (ver-
sus renin), making it even more difficult to show a rise in AGA on top of already low re-
nin-mediated AGA. A further complicating factor is that tissue homogenization per se 
may result in (partial) prorenin activation. In summary, given the presence of prorenin 
in blood plasma, brain homogenates should minimally contain the amount of prorenin 
present in a few mL of blood. The rises in AGA after prorenin activation are consistent 
with this view, but should still be interpreted with caution given the fact that non-re-
nin enzymes also came into play after acid activation. Brain-selective prorenin rises, 
e.g. after DOCA-salt, were not observed. This implies that prorenin-(pro)renin receptor 
interaction is unlikely to occur in the mouse brain, particularly after DOCA-salt (which 
lowers brain (pro)renin), although it may obviously occur after intracerebroventricular 
infusion of pharmacological prorenin doses into the brain [10]. 
Most, if not all, studies on brain renin relied on the detection of renin mRNA in 
the brain, either under normal conditions, or after deleting/overexpressing sREN or 
icREN. Deleting sREN in neurons or glia did not affect blood pressure, heart rate, water 
intake, or metabolic rate [25], while preservation of icREN did not compensate for the 
consequences of whole body sREN-deficiency (hypotension, renal defects, lethality) 
[26]. Surprisingly, brain-selective deletion of icREN even caused neurogenic hyperten-
sion, possibly because icREN inhibits sREN [8]. These data seem to argue against icREN 
as an Ang I-generating enzyme. Yet, overexpressing either human icREN or sREN in 
astrocytes, if combined with human angiotensinogen, resulted in Ang II-dependent 
hypertension and an increase in drinking volume [27]. Since icREN under the latter 
conditions was not detectable in cerebrospinal fluid (CSF), it was concluded that this 
phenomenon involved intracellular Ang II formation. We attempted to detect renin 
mRNA, using either specific assays for sREN or icREN, or a non-specific assay that de-
tects both sREN and icREN. Under no condition were we able to show renin (secreted 
+ intracellular), sREN or icREN gene expression in any of the different regions of the 
brain: the expression level was below the detection threshold of the RT-PCR assay, 
even with the use of the highly sensitive Taqman probes. The specificity of our renin 
primers was validated by making use of the kidneys of Ren1c-/- mice. Of course, poor 
renin expression in the brain has been noted before [28-30]. Because of the technical 
limitations inherent in any RT-PCR assay, we could not load more than 100 ng of total 
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RNA. Our results therefore indicate that, if renin is expressed in the brain, its expression 
is >218-fold lower than that in the kidney (no signal after 40 cycles, with renin detec-
tion in the kidney at Ct=22). The IPA expression data sets confirm this view. Yet, Kubo 
et al. observed a blood pressure drop after intraventricular renin antisense injection 
in SHR [31]. In their hands only one of three tested antisense oligonucleotides acted 
hypotensive, and this response was accompanied by a 20% drop in renin mRNA (de-
tected after 45 cycles of RT-PCR). These authors did not measure renin levels in brain or 
plasma, and were unable to rule out antisense leakage to the kidney. Therefore, these 
data cannot be taken as definitive proof for the existence of an independent brain RAS. 
The mouse RAS differs from the human RAS, in that the circulating renin levels 
in mice are up to 1000-fold higher (on a ng Ang I/ml.hr basis) than in humans. As a con-
sequence, circulating angiotensinogen levels in mice are far below Km range, as con-
firmed in the present study. Nevertheless, despite these differences, mouse angioten-
sin levels in blood and tissue are comparable to those in humans, rats and pigs [32-35]. 
We attempted to measure angiotensinogen in the mouse brain, both at the mRNA and 
protein level. Although we did observe angiotensinogen mRNA expression in different 
regions of the brain, in full agreement with previous work [36-37], expression was up 
to 500-fold lower than in the liver. Under no condition were we able to detect an-
giotensinogen protein in the brain. Given the detection limit of our assay (1 pmol/g), 
this implies that brain angiotensinogen, if present, occurs at levels (per g tissue) that 
are <3% of the levels in plasma (per mL plasma). Such low levels have been reported 
before in the rat brain, as well as in human and rat CSF [16,38-40], and thus our data 
entirely agree with the literature. Clearly, mice, given their low angiotensinogen levels, 
are not the optimal species to study brain angiotensinogen. As astrocytes are assumed 
to be the source of brain angiotensinogen [41-42], we additionally studied angioten-
sinogen synthesis by rat primary cortical astrocytes, but again failed to detect any an-
giotensinogen. Nevertheless, data from Schink et al. [40] do support the functional 
presence of angiotensinogen in the rat brain. These authors artificially elevated renin 
in the brain by either intracerebroventricular renin infusion (in Sprague-Dawley rats) 
or by making use of transgenic hypertensive rats overexpressing mouse Ren2. The 
responses to both approaches (drinking and blood pressure reduction, respectively) 
were greatly diminished after lowering brain angiotensinogen by brain-selective ex-
pression of an antisense RNA against angiotensinogen mRNA. 
Finally, given our observation that brain renin is confined to the plasma com-
partment, while brain angiotensinogen is extremely low (if not also confined to the 
plasma compartment), an urging question is what degree local angiotensin genera-
tion truly occurs in the brain. We therefore collected brainstem tissue (i.e., the brain 
region with the highest renin level) from SHR under control conditions and during RAS 
blockade with olmesartan or lisinopril. Rats rather than mice were used here, because 
at identical angiotensin levels in both species, the larger rat brainstem would allow a 
more reliable quantification of angiotensins. Without treatment, brain Ang I was un-
detectable, while Ang II occurred at levels that were ≈25% of the levels in plasma (per 









higher than in plasma, while Ang I is easily detectable [43-46]. RAS blockade induced 
the usual rise in Ang I levels in plasma, and now brain Ang I became detectable, how-
ever, at only 1% (v/v) of its plasma levels. It seems reasonable to assume that also in the 
untreated animals brain Ang I levels were in the 1% range of plasma Ang I, and there-
fore too low to be detected with our assays. If so, this implies that under all conditions, 
brain Ang I at most represented the amount of Ang I that is inherently present in brain 
tissue because it contains a small amount (≈1%) of blood [16]. Lisinopril decreased 
brain Ang II to undetectable levels, while olmesartan reduced the brain/plasma Ang 
II ratio by >80%. The latter finding suggests that, normally, circulating Ang II accumu-
lates in brain tissue via binding to AT1 receptors. Such uptake occurs in multiple organs 
[47], and facilitates the intracellular accumulation of Ang II [48]. Without receptors (i.e., 
in AT receptor-deficient mice), tissue Ang II levels drop dramatically [49], suggesting 
that tissue Ang II levels do not originate intracellularly. If Ang II binding to AT1 recep-
tors is the only source of Ang II in the brain, one would expect angiotensin metabolites 
that do not (or only with low affinity) bind to this receptor to be undetectable in the 
brain. This is indeed what we observed for both Ang-(2-8) and Ang-(1-7). An olmesar-
tan-induced reduction in brain Ang II levels was also observed in Dahl-sensitive hyper-
tensive rats, albeit in the absence of an effect on blood pressure [50]. Clearly therefore, 
the changes observed in brain Ang II are blood pressure-independent. 
PERSPECTIVES
The absence of renin-dependent AGA in the brain outside the blood compart-
ment implies that angiotensin generation in the brain, if occurring, does not involve 
renin. Brain prorenin levels, if anything, were even lower than brain renin levels, and 
therefore, like renin, at most represented the amount of prorenin expected in brain tis-
sue based upon its blood content. Selective brain prorenin upregulation, e.g. after DO-
CA-salt, could not be observed, arguing against the concept that DOCA-salt-induced 
neurogenic hypertension involves prorenin-(pro)renin receptor interaction. Finally, 
the absence of Ang I in brain tissue outside the blood compartment (which contrasts 
sharply with the presence of Ang I in every other organ of the body) strongly suggests 
that there is no local Ang I generation in the brain. Apparently therefore, non-renin 
enzymes do not compensate for the absence of renin, assuming at least that brain 
angiotensinogen levels are of sufficient magnitude to allow independent Ang I gener-
ation at all. Only ex vivo, after prohormone-activating procedures, did we occasionally 
obtain evidence for a very modest contribution of such non-renin enzymes, but the 
in-vivo relevance of these findings is questionable. Brain Ang II therefore appears to 
originate in the blood compartment. Of course, circulating Ang II will bind to brain AT 
receptors that are outside the blood-brain barrier (e.g., in the circumventricular organ). 
Yet, it may also gain access to brain areas behind this barrier, e.g. under conditions 
where blood-brain barrier permeability is compromised, like in (DOCA-salt) hyperten-
sion [51-52]. In fact, Ang II itself may be responsible for disturbing the blood-brain 
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barrier, thus facilitating its own access to critical brain areas like the hypothalamus 
and brainstem. From this perspective, the brain ‘RAS’ in reality represents circulating 
Ang II that accumulates in brain nuclei, possibly after it has (partially) broken down 
the blood-brain barrier. This Ang II subsequently activates sympatho-neurohumoral 
outflow, for instance by upregulating reactive oxygen species [52-53]. This is entirely 
different from other organs like heart, kidney and vascular wall, where renin and an-
giotensinogen diffuse freely into the interstitial space, allowing local production of 
Ang I to occur [20,54-55]. Blocking AT1 receptors or enhancing Ang II degradation (e.g., 
by ACE2) will prevent the effects of circulating Ang II in the brain, thereby explaining 
the success of intracerebroventricular application of losartan or brain-selective ACE2 
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The function of prorenin, the inactive precursor of renin, remains unclear after many 
decades of research. The discovery of a (pro)renin receptor suggested that prorenin, 
by binding to this receptor, would become active, i.e., obtain an ‘open’ conforma-
tion. However, the receptor only interacted with prorenin at levels that were many 
orders of magnitude above its normal levels, making such interaction in vivo unlike-
ly. Prorenin occurs in 2 conformations, an open, active form, and a closed, inactive 
form. Under physiological conditions (pH 7.4, 37°C), virtually all prorenin occurs in 
the closed conformation. This study investigated to what degree prorenin-synthe-
sizing cells release prorenin in an open conformation. Renin- and prorenin-synthe-
sizing human mast cells, and prorenin-synthesizing HEK293 cells (transfected with 
the mammalian expression vector pRhR1100, containing human prorenin) and hu-
man decidua cells were incubated with the renin inhibitor VTP-27999. This inhib-
itor will trap open prorenin, since after VTP-27999 binding, prorenin can no longer 
return to its closed conformation, thus allowing its detection in a renin immunora-
diometric assay. No evidence for the release of open prorenin was found. Moreover, 
incubating decidua cells with angiotensinogen yielded low angiotensin levels, cor-
responding with the activity of ≈1% of prorenin in the medium, i.e. the amount of 
open prorenin expected based upon the equilibrium between open and closed 
prorenin under physiological conditions. Our study does not reveal evidence for 
the release of open, active prorenin by prorenin-synthesizing cells, at least under 
cell culture conditions. This argues against prorenin activity at the site of its release. 
INTRODUCTION
Renin belongs to the A1 family of aspartic proteases. Its 3D structure consists of 
two β-sheet domains, the N- and C-domain. Renin has an inactive precursor, prorenin, 
in which the catalytic binding site is covered by the N-terminal part of mature renin 
that, in turn, is covered by the prosegment [1]. After removal of the prosegment, this 
N-terminal part becomes part of a six-stranded β-sheet on the back of the mature re-
nin molecule, previously occupied by the prosegment. This requires a conformational 
change that fully exposes the active cleft [1]. 
Prosegment unfolding occurs in a pH- and temperature-dependent manner, 
and, if not followed by cleavage, results in two prorenin conformations (Figure 1): a 
‘closed’, inactive form, and an ‘open’ form that displays full enzymatic activity [2, 3]. In 
addition, an intermediate form exists where the prosegment has moved away from 
the cleft, but where the renin part still has to undergo the afore-mentioned conforma-
tional changes. Under physiological conditions (pH 7.4, 37°C), <2% of prorenin is in the 
open conformation. The renin inhibitor aliskiren binds to prorenin in the open confor-
mation as well as to the intermediate form of prorenin [2, 3]. Binding to the intermedi-
ate form induces prorenin unfolding. Due to the tight binding of the renin inhibitor, 









ble, and thus, the equilibrium between the closed and open conformation will shift in 
favor of the open conformation. Eventually, all prorenin molecules may be open 
(‘non-proteolytic activation’), allowing its recognition by the active site-directed anti-
bodies used in renin immunoradiometric assays (IRMAs), despite the fact that the 
prosegment is still present and aliskiren is bound to the active site [4, 5]. 
Unexpectedly, VTP-27999, a new, active site-directed renin inhibitor with an IC50 
(0.3 nmol/L) that is comparable to that of aliskiren, did not induce prorenin unfolding 
[6]. Yet, it blocked the aliskiren-induced unfolding of prorenin. This suggest that VTP-
27999 does bind to the intermediate form of prorenin, but that such binding has no 
conformational consequences. Furthermore, VTP-27999 increased renin immunoreac-
tivity. This may relate to the observation, based on crystallization studies, that there 
are 2 renin conformations [7]. Aliskiren and VTP-27999 bind to both conformations, 
but only in the case of VTP-27999, the conformations of the two monomers are nearly 
identical [6]. These conformational differences are likely to affect the affinity of the ac-
tive site-directed antibodies applied in renin IRMAs. As a consequence, the renin IRMA 
yields higher levels in the presence of VTP-27999 than without this inhibitor. 
A long-standing question concerns the function of prorenin. As mentioned 
above, it displays limited activity in plasma. Nguyen et al. proposed that it binds to 
Figure 1. Model displaying the closed and open prorenin conformations, as well as the assays 
allowing the detection of these prorenin variants. Normally, <2% of prorenin is in the open 
conformation. Aliskiren, acid and low temperature shift the equilibrium to the right, allowing the 
detection of prorenin in a renin IRMA, on the basis of its prosegment (F258 IRMA), or by enzyme-
kinetic assay (EKA). Only a direct prorenin ELISA allows the detection of intact, closed prorenin. 
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the so-called (pro)renin receptor at nanomolar affinity [8]. This resulted in a conforma-
tional change, allowing prorenin to display full activity. Theoretically, this would result 
in angiotensin generation, at least in (pro)renin receptor-expressing tissues, by recep-
tor-bound prorenin. Initially, this finding was received with great enthousiasm, since 
it finally provided a role for prorenin: although synthesized in only a limited number 
of organs, given the wide occurrence of the (pro)renin receptor, prorenin might now 
contribute to angiotensin generation in virtually every organ of the body. However, 
although in-vitro studies applying high prorenin concentrations confirmed this con-
cept, the prorenin concentrations in vivo are many orders below its Kd for the (pro)
renin receptor, thereby making this possibility unlikely [9, 10]. As a consequence, this 
concept is now being abandoned, and we need alternative hypotheses to explain the 
function (if any) of prorenin. One possibility is that prorenin acts exclusively at its site 
of synthesis. For this to occur, prorenin-synthesizing cells should release prorenin in an 
open conformation, allowing it to display local activity in the immediate vicinity of the 
cells, before it returns to its inactive, closed conformation, e.g., when reaching blood 
plasma. If true, renin inhibitors capable of interfering with open prorenin might have 
an advantage over other RAS blockers, since they can specifically suppress angiotensin 
generation in prorenin-synthesizing tissues. Possibly, novel inhibitors need to be de-
veloped to optimally exert this effect. 
To test this concept in the present study, we made use of human prorenin-syn-
thesizing cells. For comparison, renin-releasing cells were also evaluated. We used 3 
approaches. First, we incubated the cells with VTP-27999. This inhibitor, like aliskiren, 
would bind to prorenin if it is released in an open conformation, thus preventing its 
return to the closed conformation, allowing its detection in a renin IRMA. VTP-27999, 
unlike aliskiren, would not additionally convert all closed prorenin molecules into the 
open conformation, and thus  this renin inhibitor is ideal to quantify the percentage 
of prorenin molecules released in the open conformation. We applied renin-, pro-
renin-, and prosegment-specific assays (available for human (pro)renin only) to verify 
this concept. Second, we studied angiotensin I generation during prorenin release by 
adding angiotensinogen to the medium, the underlying assumption being that only 
open prorenin would be able to display enzymatic activity. Finally, we verified to what 
degree prorenin in human plasma displays angiotensin I-generating activity. 
METHODS
Human samples 
All studies were approved by the Medical Ethical Review Board, and performed 
in accordance with the Declaration of Helsinki and Good Clinical Practice. Informed 
consent was obtained from each subject. Blood samples were obtained from 6 healthy 
controls (4 men, 2 women; age 23-45 years, mean 31 years). Blood was collected in 
polystyrene tubes containing 6.25 mmol/L EDTA (final concentration). The samples 









used immediately or stored at -20°C. Placenta’s were harvested from 7 women after 
delivery (age 26-41, mean 34 years). Renin- and prorenin-synthesizing human mast 
cells (HMC-1) were a gift from Dr. J.H. Butterfield (Mayo Clinic, Rochester, MN, USA) [11].
Cell culture studies
Cell culture studies were performed at 37°C in a humidified 5% CO2 incubator 
(Sanyo, Panasonic Biomedical Sales Europe B.V., Etten-Leur, The Netherlands). 
HMC-1 cells were cultured in 75 cm2 culture flasks using Iscove’s modified Dul-
becco’s medium (Lonza, Verviers, Belgium), supplemented with 10%, iron-supple-
mented bovine calf serum (Hyclone, Thermo Fisher Scientific, Breda, The Netherlands), 
1% Penicillin Streptomycin (PS; Invitrogen, Bleiswijk, The Netherlands) and 1.2 mmol/L 
α-thio-glycerol (Sigma, Zwijndrecht, The Netherlands). 
HEK293 cells were transfected with the mammalian expression vector 
pRhR1100, containing human prorenin [12], a gift from Dr. Reudelhuber (IRCM, Mon-
tréal, Canada). In short, cells were transfected with Lipofectamine2000 (Invitrogen), 
according to the manufacturers protocol, and put on selection using 0.6 mg/mL G418 
(Invitrogen). The clone with the highest expression of prorenin was isolated, and used 
for further experiments. Cells were cultured in DMEM-F12 (GIBCO, Breda, The Nether-
lands) medium supplemented with 10% fetal calf serum (FCS; Lonza), 1% PS, and 0.6 
mg/mL G418. 
Decidua cells were harvested from the maternal side of the placenta accord-
ing to Markoff et al. [13]. In short, tissue was chopped and washed twice with DPBS 
(GIBCO), alternated by centrifugation steps of 10 minutes at 700 rpm. The pellet was 
resuspended in 5 mL RPMI-1640 (GIBCO) per gram tissue, supplemented with 1% FCS, 
0.1% collagenase and 0.1% hyaluronidase (Sigma) in a tissue culture flask, and put on 
an orbital shaker (150 rpm) for two hours at 37°C. This suspension was filtered using 
a sieve with a mesh of 40 µm. The filtered solution was centrifuged for 10 minutes at 
700 rpm, after which the pellet was washed with RPMI-1640, and centrifuged again. 
The pellet was then exposed to 20 mL RBC lysis solution (5PRIME, Hilden, Germany) 
for 10 minutes, followed by another 10 minutes of centrifugation. This was followed by 
another two wash steps with RPMI. Next, cells were cultured in RPMI-1640 containing 
10% FCS, 12.5 mmol/L HEPES (GIBCO), 50 µg/mL gentamycin (Sigma) and 5 µg/mL 
fungizone (Sigma). Medium was changed every 24 hours in the first 72 hours. 
For experiments verifying the release of open prorenin, cells were seeded in 
6- or 12-well plates at a concentration of 0.5*106 cells/mL in fresh medium in the pres-
ence or absence of VTP-27999 (0.1-1000 nmol/L). After 2 to 5 days, medium was col-
lected, and spun down 5 minutes at 2500 rpm to remove remaining cells. Supernatant 
was stored at -20°C. 
To study prorenin-induced angiotensin generation, decidua cells were incubat-
ed for 24 hours in the presence of 150 nmol/L human angiotensinogen (Sigma). Cells 
incubated without angiotensinogen served as control. Medium samples (75 mL) for the 
determination of renin and prorenin were collected at 4, 8 and 24 hr. Medium samples 
(500 mL) for the determination of angiotensin I were collected at 24 hours with 25 mL 
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inhibitor stock solution (containing 0.1 mmol/L aliskiren, 200 mmol/L EDTA and 0.2 
mmol/L lisinopril), frozen in liquid N2, and stored at -70°C. The first-order rate constant 
for angiotensin I elimination was determined by incubating the cells with 100 nmol/L 
angiotensin I for maximally 4 hrs in the presence or absence of 100 nmol/L captopril. 
Medium samples (50 mL) for the determination of angiotensin I were collected at 0, 0.5, 
1 and 4 hr, mixed with 2.5 mL inhibitor stock solution, and stored as described above. 
Biochemical assays 
Renin and prorenin were determined either indirectly, by enzyme-kinetic assay 
(i.e., quantifying angiotensin I-generating activity) or directly, by IRMA (i.e., quantifying 
renin or prorenin immunoreactively). 
Enzyme-kinetic assays were applied to human plasma samples only, to verify 
prorenin activity. The sample was incubated with excess sheep angiotensinogen in the 
presence of angiotensinase inhibitors, either directly after its removal from the patient, 
after freezing and thawing, or after keeping it for 18 hours at 37°C. Imidazole buffer 
(final concentration 0.1 mol/L) was added to the incubation mixture to keep pH at 7.4.
Immunoreactive renin was measured with the Renin III (Cisbio, France) IRMA. 
This assay, which makes use of a monoclonal antibody (4G1) [14] directed against re-
nin’s active site, also recognizes intact, open prorenin [2, 15]. This implies that intact 
prorenin can be measured with this assay after incubating it with acid (pH=3.3) or after 
exposing it for 48 hours at 4°C to 10 mmol/L aliskiren, since both procedures induce the 
conversion of all prorenin molecules into the open conformation [4]. 
Intact, closed prorenin was measured with an enzyme-linked immunosorbent 
assay (ELISA) that recognizes residues 32-39 of the prosegment (Molecular Innova-
tions, Novi, MI, USA) [3]. This prorenin assay was performed according to the instruc-
tions of the manufacturer, making use of human recombinant prorenin to construct 
the standard curve. 
In a select set of samples, intact, open prorenin was measured on the basis of its 
prosegment, replacing the 125I-labeled active site-directed monoclonal antibody of the 
Cisbio kit by a prosegment-directed 125I-labeled monoclonal antibody (F258-37-B1) in 
the IRMA (‘F258 IRMA’). F258-37-B1 is directed against the C-terminal part (p20-p43) of 
the propeptide and does not react (<0.1%) with renin. F258-37-B1 also does not react 
(<0.1%) with intact, closed prorenin [16]. However, it does react with prorenin after 
the converting all prorenin molecules into the open conformation by incubation with 
acid. Thus, the acid-induced non-proteolytic conformational change, causing the pro-
peptide to move to the surface of the molecule, allows the recognition of prorenin by 
both the active site-directed antibody of the Cisbio kit, and the prosegment-directed 
antibody of the prorenin IRMA.
Angiotensin I and II levels in the medium were measured by radioimmunoassay 











Results are shown as mean±SEM. Differences were tested using one-way ANO-
VA, followed by Dunnett’s multiple comparison test; P<0.05 was considered signifi-
cant. Angiotensin I–generating activities obtained in the enzyme-kinetic assay were 
converted to renin concentrations based on the fact that 1 ng of angiotensin I per 
milliliter per hour corresponds with 2.6 pg of human renin per milliliter [18].
RESULTS
Plasma prorenin displays enzymatic activity
When incubating freshly obtained plasma samples from 6 healthy controls with 
excess angiotensinogen at 37°C, angiotensin I generation was linear over time (Figure 
2, left panel). Results obtained in the same samples after they had been frozen and 
thawed were identical. However, when performing the assay after the samples had 
been kept for 18 hours at 37°C (to inactivate open prorenin) the degree of angioten-
sin I generation was lower (P<0.05). This was not due to (pro)renin degradation, since 
total renin levels (determined by immunoreactive assay) did not change over the 18 
hour-period (Figure 2, right panel). The average decrease in angiotensin I-generating 
activity after 18 hours (≈1 ng angiotensin I/mL.hr) corresponded with ≈3% of the im-
munoreactive prorenin levels. This confirms that both blood handling/centrifugation 
(at room temperature) and freezing/thawing induce a conformational change in pro-
renin, allowing a small percentage of the prorenin molecules to display enzymatic 
activity in the enzyme-kinetic assay. Prolonged incubation at 37°C reversed this phe-
nomenon.
VTP-27999 increases renin immunoreactivity, but does not unravel the release 
of ‘open’ prorenin 
Open prorenin release was studied in cells that synthesize both renin and 
prorenin (HMC-1 cells) and in cells that exclusively synthesize prorenin (human pro-
renin-expressing HEK293 cells and decidua cells). 
In medium samples obtained from HMC-1 cells incubated without inhibitor, re-
nin was measured by renin IRMA, both before and after activating prorenin with ali-
skiren (i.e., converting all closed prorenin molecules to open prorenin molecules). Ali-
skiren exposure increased renin immunoreactivity ≈3-fold (Figure 3, left panel; n=7), 
illustrating that the cells predominantly released prorenin. Total renin measurements 
after aliskiren exposure did not change significantly following incubation of the cells 
with increasing concentrations of VTP-27999, nor did prorenin immunoreactivity (de-
termined by prorenin ELISA) change in the presence of this inhibitor. This implies that 
VTP-27999 did not affect (pro)renin release per se. Yet, renin immunoreactivity (ex-
pressed as a % of the total renin levels without VTP-27999) almost tripled following 
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incubation of the cells with VTP-27999 (Figure 3 left panel; n=6). Given the absence of 
changes in the release of (pro)renin, these data suggest that VTP-27999 affects the re-
nin assay itself (i.e., yields higher renin levels for a given amount of renin). 
Aliskiren increased renin immunoreactivity in the medium of control (i.e., in-
cubated without inhibitor) HEK293 and decidua cells >10-fold (Figure 3, middle and 
right panels; n=5). This is in agreement with the fact that these cells exclusively release 
prorenin, and that, at pH=7.4 and 37°C, only a few percent of prorenin is in the open 
conformation (i.e., can be recognized in a renin IRMA). Total renin measurements after 
aliskiren exposure did not change following incubation of the cells with increasing 
concentrations of VTP-27999, nor did prorenin immunoreactivity change in the pres-
ence of this inhibitor. Thus, as in HMC-1 cells, VTP-27999 did not affect prorenin release 
in either HEK293 cells or decidua cells. Yet, VTP-27999 doubled renin immunoreactivity 
in both cell types.
The latter increase in renin immunoreactivity might be suggestive for the re-
lease of open prorenin. To verify this further, we first repeated the studies in (pro)re-
nin-containing medium (obtained from control cells) incubated with VTP-27999 in the 
absence of cells. Results were identical (Figure 4; n=5-7). Second, we exposed (pro)re-
nin-containing medium of the 3 cell types to acid, to induce the open (renin-like) con-
formation in all prorenin molecules. Under this condition, the prosegment is still pres-
ent, but folded away from the active site (allowing prorenin detection both by renin 
Figure 2. Left, angiotensin I generation in human plasma during its incubation with excess sheep 
angiotensinogen, either immediately after collecting the plasma samples (fresh), after keeping 
the samples for 18 hours at 37°C, or after freezing and thawing the samples. Right, renin and total 









- and prosegment IRMA). Next, pH was returned to pH=7.4 in the absence or presence 
of either 10 mmol/L aliskiren or VTP-27999. Without renin inhibitor, prorenin will rapid-
ly return to its closed conformation, no longer allowing its detection by renin - or 
prosegment IRMA. But with renin inhibitor, prorenin will be trapped in its open confor-
mation, allowing its detection in both IRMAs. Results show that both renin inhibitors 
greatly increased renin and prosegment immunoreactivity (Figure 5, n=3 for all condi-
tions), confirming their capacity to trap prorenin in its open conformation. Important-
ly, the increases in renin immunoreactivity after VTP-27999 were ≈20-fold, i.e. double 
those seen after aliskiren. In contrast, the increases in prosegment immunoreactivity 
were identical for both inhibitors. This implies that VTP-27999 increases renin immu-
noreactivity, but not prosegment immunoreactivity. 
Taken together, these data show that incubation of all 3 cell types with VTP-
27999 yields higher renin immunoreactivity levels in the medium. Yet, this is due to the 
fact that VTP-27999, for a given amount of renin or open prorenin, increases renin im-
munoreactivity in the renin IRMA 2-3 fold. It is not due to the release of open prorenin, 
since a) results were identical in the absence of cells, and b) renin immunoreactivity 
rises in the medium of prorenin-releasing cells were far below the 20-fold that would 
have been expected had all prorenin been released in the open conformation. 
Figure 3. Renin, total renin (measured following after aliskiren pretreatment) and prorenin in the 
medium of renin+prorenin-secreting HMC-1 cells or exclusively prorenin-secreting HEK293 and 
decidua cells, cultured in the presence of increasing concentrations VTP-27999. Renin and total renin 
were measured by renin IRMA, prorenin was measured by direct prorenin ELISA. Data are mean±SEM 
of n=5-7, and have been expressed as a percentage of the total renin levels without VTP-27999. 
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Angiotensin generation in decidua cells
The medium prorenin levels of decidua cells continuously rose during a 24 
hour-incubation (Figure 6, left panel; n=3-7). Angiotensin I, when added to these cells, 
disappeared with a half life (t1/2) of 0.45±0.04 hr (n=7). In the presence of captopril, the 
angiotensin I half life increased to 1.41±0.13 hr (P<0.01), implying that 66±4% of the 
angiotensin I metabolism was due to conversion by ACE (Figure 7, left panel). Impor-
tantly, the angiotensin I disappearance was identical when repeating these studies in 
(serum-containing) medium in the absence of cells (n=5), suggesting that the majority 
of the angiotensin I metabolism involved serum-derived ACE (Figure 7, right panel). In 
other words, we found no evidence for the presence of decidual ACE. Consequently, 
when investigating angiotensin generation after adding angiotensinogen, we only fo-
cused on angiotensin I, and not angiotensin II. Angiotensin I levels in the medium at 24 
hours after adding angiotensinogen were 4-5 times higher than the (background) lev-
els measured in the absence of angiotensinogen (Figure 6, right panel; n=7). Normally, 
2.6 pg/mL renin corresponds with 1 ng angiotensin I/ml.hr  (vmax), at least when activity 
is determined at angiotensinogen levels above Km (=1200 nmol/L). However, our ex-
periments were performed at angiotensinogen levels 8 times below Km (150 nmol/L). 
This implies that angiotensin I generation in our experimental set-up occurred at a rate 
Figure 4. Renin and total renin (measured following after aliskiren pretreatment) in medium 
obtained from renin+prorenin-secreting HMC-1 cells or exclusively prorenin-secreting HEK293 
and decidua cells, incubated without cells in the presence of increasing concentrations VTP-
27999. Renin and total renin were measured by renin IRMA. Data are mean±SEM of n=5-









v corresponding with v = 150/(150+1200) x vmax. Given the angiotensin I half life of 0.45 
hr, the expected steady-state level of angiotensin I level can be calculated as v x t1/2/
ln2. Had all prorenin detected at 24 hours been active, this steady-state angiotensin I 
level would have been 12109±4488 fmol/mL. In reality, the steady-state angiotensin I 
levels at that time point amounted to only 1.3±0.7% of this level. This suggest that ≈1% 
of prorenin displayed enzymatic activity under our experimental conditions. This is 
comparable to the percentage of ‘active’ prorenin in human plasma, and thus opposes 
the concept that prorenin-synthesizing cells release open prorenin.  
DISCUSSION
The current study, making use of human prorenin-releasing cells, does not 
provide evidence for the concept that such release occurs in an ‘open’ conformation, 
subsequently allowing prorenin to display (full) activity at the site of its release. Theo-
retically, given the low pH conditions under which (pro)renin synthesis/release occurs 
[19], this might have happened, given that a low pH shifts the equilibrium between 
the open and closed conformation of prorenin into the direction of the former. Our 
data in acid-pretreated medium samples (containing 100% open prorenin [20]) con-
firm that the renin inhibitor VTP-27999 would have kept prorenin in this open confor-
mation, allowing its detection in a renin assay, or an assay detecting the prosegment.  
The renin inhibitor aliskiren would have done the same. However, this inhibi-
tor, unlike VTP-27999, also affects the equilibrium between the open and closed con-
formation by inducing a conformational change in prorenin [4]. Therefore, aliskiren, if 
applied at sufficiently high concentrations, would have converted all closed prorenin 
molecules into the open conformation. This would have resulted in an overestimation 
of the number of open prorenin molecules, and thus aliskiren cannot be used to quan-
tify the release of open prorenin.
Figure 5. (Pro)renin immunoreactivity, measured by renin IRMA (open bars) or prosegment (F258) 
IRMA (closed bars) in the acid-pretreated medium of HMC-1 cells, HEK293 cells or decidua cells, 
followed by a 1-hour incubation with buffer (control), 10 µmol/L aliskiren (acid+ali), or 10 µmol/L 
VTP-27999 (acid+VTP). # P<0.05 vs. control. *P<0.05 vs. aliskiren. Data are mean±SEM of n=3. 
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When applying VTP-27999 to cells that release renin (HMC-1 cells), we observed 
that this inhibitor increased renin immunoreactivity 2-3-fold. This has been observed 
before in human plasma [6], and is related to the existence of 2 renin conformations 
[7], and the different affinity of the active site-directed antibody for these 2 conforma-
tions. The immunoreactivity increase also occurred when applying VTP-27999 to ac-
id-activated prorenin, i.e., prorenin that has the open conformation. This confirms that 
the 3D structure of open prorenin resembles that of renin, despite the fact that the 
prosegment is still present [2]. Since VTP-27999 did not affect the outcome of the 
prosegment assay (F258 IRMA), it can be concluded that the binding of VTP-2799 to 
renin’s active site selectively affected the affinity of the active site-directed antibody. 
Under physiological conditions, only a small percentage of prorenin is in the 
open conformation [2]. This was also the case in the medium of our HEK293 and decid-
ua cells (i.e., cells that exclusively released prorenin). Therefore VTP-27999 should have 
minimally bound to this percentage of the prorenin molecules, and, given its effect on 
the affinity of the active site-directed antibody, it might subsequently marginally have 
increased renin immunoreactivity in the renin IRMA. This is indeed what happened: no 
substantial rises in renin immunoreactivity were observed after VTP-27999, although 
a >20-fold rise would have been feasible (Figure 5) in case all prorenin molecules 
would have been released in an open conformation. Moreover, the rises observed in 
prorenin-containing medium incubated with VTP-27999 in the absence of cells were 
identical to those observed with cells. These data therefore strongly argue against the 
release of open prorenin. 
In addition, our angiotensin measurements after applying human angioten-
sinogen to the medium of human decidua cells also do not support the release of 
open, active prorenin. At most, the generated levels of angiotensin I in the medium of 
these cells support the idea that ≈1% of prorenin displayed activity, i.e., is in the open 
Figure 6. Left, total renin levels in the medium of human decidua cells after 4, 8 and 24 hours 
(mean±SEM of n=3-7) in the absence (open bars) or presence (closed bars) of 150 nmol/L human 
angiotensinogen. Levels were measured by renin IRMA after prorenin activation with aliskiren. 
Right, angiotensin I levels in the medium of human decidua cells after 24 hours (mean±SEM of 









conformation. Such low percentages are in the range occurring in human blood plas-
ma, and simply represent the open/closed equilibrium at pH=7.4 and 37°C, i.e., our cell 
culture conditions [20-22]. Lowering temperature will increase this percentage, as con-
firmed by our measurements in human plasma, and only keeping the samples for a 
prolonged time at 37°C allowed prorenin to refold into its closed, inactive conforma-
tion. Clearly, depending on the assay conditions, prorenin may be detected as renin, 
and given its much higher levels than those of renin, this should be taken into account 
when quantifying renin in patients with low renin levels [23]. Decidua cells neither re-
leased angiotensinogen themselves, nor generated ACE. Yet, these components are 
present in the 10% FCS added to the medium [24], and obviously this should be cor-
rected for when studying angiotensin generation by decidua cells. 
In summary, the function of prorenin, if any, remains elusive. The discovery 
of the (pro)renin receptor [8] caused a lot of excitement, but recent studies have re-
vealed that its in-vivo function in reality is largely, if not entirely, prorenin-indepen-
dent [25-27]. All studies investigating prorenin binding to this receptor applied highly 
non-physiological concentrations, which have no relevance in vivo [10, 28]. Our cur-
rent studies do not reveal evidence for the release of open, active prorenin by pro-
renin-synthesizing cells. This argues against prorenin activity at the site of its release, 
at least when applying cell culture conditions, but does not exclude that there are 
sites where prorenin may display activity. At such sites, either a prorenin-activating 
enzyme should be present, or conditions favouring prorenin unfolding, e.g. a low pH 
or a novel, high-affinity prorenin-binding receptor. Finally, to minimize the contribu-
tion of prorenin in renin assays, samples should not be exposed to low temperatures 
Figure 7. Left, angiotensin I levels in the medium of human decidua cells in the presence 
(closed circles) or absence of 100 nmol/L captopril (open squares) after adding 100 nmol/L 
angiotensin I at t=0. Right, angiotensin I levels in medium alone (i.e., without cells), in the 
presence or absence of 100 nmol/L captopril after adding 100 nmol/L angiotensin I at t=0. 
Data are mean±SEM of n=5-7, and have been expressed of the levels of angiotensin I at t=0.
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and preferably be incubated immediately. However, since this is not feasible in daily 
clinical practice, the best is to centrifuge them at room temperature (i.e., not at 4°C), 
to freeze and thaw the samples only once, and to incubate them as long as possible at 
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Renin is filtered by the glomerulus, and subsequently reabsorbed in the proximal tu-
bule in a megalin-dependent manner, as evidenced by a 20-40-fold rise in urinary renin 
in patients with Dent disease or Lowe syndrome, i.e. disorders characterized by defec-
tive proximal tubular reabsorption. Remarkably, the reabsorption of filtered prorenin 
in healthy subjects appears to be complete. To further investigate megalin-mediated 
renin and prorenin reabsorption, human conditionally immortalized proximal tubule 
epithelial cells (ciPTEC) were incubated at 37°C or 4°C with recombinant human renin 
or prorenin (1000 U/L), in the absence or presence of the mannose 6-phosphate (M6P) 
receptor blocker M6P or the recombinant megalin ligand receptor-associated protein 
bound to glutathione-S-transferase (RAP-GST). Cell lysate (pro)renin levels were mea-
sured by immunoradiometric assay both before and after prorenin activation. At 37°C, 
cellular renin and prorenin accumulation leveled off after 6-8 hours, and the majority 
of prorenin was efficiently converted to renin. Incubating ciPTEC at 4°C diminished 
the cellular accumulation of renin and prorenin by ≈90%, and at this temperature pro-
renin remained in its inactive conformation. Both M6P and RAP-GST blocked renin and 
prorenin uptake by >80% at 37°C, without affecting prorenin activation. Blocking ef-
fects at 4°C were more modest. Importantly, M6P blocked the uptake of fluorescently 
labeled albumin (IC50 ≈7 mmol/L) to the same degree as the megalin inhibitor RAP-
GST (IC50 ≈140 mg/mL). Since albumin is internalized in a megalin-dependent man-
ner, these data indicate that M6P, on top of blocking M6P receptors, also interferes 
with the megalin-dependent uptake process. In conclusion, ciPTEC bind and internal-
ize renin and prorenin in a time- and temperature-dependent manner. This process 
involves megalin and/or M6P receptors, and results in prorenin activation at 37°C. 
INTRODUCTION
The kidney is a major player in the maintenance of the body fluid-electrolyte 
homeostasis. This is achieved by complex mechanisms, in which 3 major processes 
occur: glomerular filtration, tubular secretion, and tubular reabsorption [1]. Kidney 
proximal tubular epithelial cells (PTEC) are responsible for 60-70% of the reabsorption 
of water, NaCl, NaHCO3,, and for the majority of the reabsorption of nutrients in the 
glomerular ultrafiltrate [2]. Fluid and electrolyte reabsorbtion by the proximal tubule 
(PT) is the result of transcellular and paracellular fluxes, with the participation of both 
active transport and passive paracellular electrochemical diffusion [3]. The uptake of 
proteins filtered by the glomerulus in the PT largely relies on the endocytic receptors 
megalin and cubilin [4]. For instance, albumin as well as the renin-angiotensin system 
(RAS) components renin and angiotensinogen are reabsorbed in the PT by endocytot-
ic uptake in a megalin-dependent manner [5]. 
Megalin is a large glycosylated receptor of 600 kDa that belongs to the low-den-
sity lipoprotein receptor family, encoded by the LRP2 gene. More than 40 ligands have 
been identified that bind to megalin by its large extracellular domain. It works in con-








cert with cubilin, a 460-kDa glycosylated extracellular protein, forming a multireceptor 
complex with the bound ligands, driving their internalization and subsequent endo-
cytosis [4, 6, 7]. Both megalin and cubilin are abundantly coexpressed in the PT apical 
(brush-border) membrane, and the physiological and pathological roles of these mul-
tiligand receptors have been detected in animal models and human allelic syndromes 
[6]. For instance, the loss-of-function mutations in either the CLCN5 gene, responsible 
for Dent-1 disease, or the OCRL gene, responsible for Dent-2 disease and Lowe syn-
drome, lead to dysfunctional receptor-mediated endocytosis and lysosomal function, 
in which the expression or trafficking of receptors (including megalin and cubilin) is 
impaired [8]. This results in low-molecular weight (LMW) proteinuria, hypercalciuria 
with nephrolithiasis, nephrocalcinosis, and other variable proximal tubular defects [8]. 
Interestingly, in patients with Dent or Lowe syndrome, both renin and angiotensino-
gen rise 20-40 fold in urine, supporting impaired reabsorption [9]. Moreover, in such 
patients prorenin becomes detectable in urine, while normally this precursor of renin 
is entirely undetectable in urine, even in patients with elevated plasma prorenin levels, 
like diabetics, or in transgenic animals with prorenin levels that are >1000-fold above 
normal [9]. 
To investigate megalin-mediated renin and prorenin reabsorption in further 
detail, we used human conditionally immortalized proximal tubules cells (ciPTEC), a 
cell line that is highly suitable to study the effect of ligands on PTEC function, since, 
unlike other cell lines, it expresses multiple influx and efflux transporters, in addition 
to the whole endocytosis machinery [10, 11]. Cells were incubated with recombinant 
human renin or prorenin at 37°C (allowing binding and internalization) or 4°C (allow-
ing binding only), in the presence or absence of the megalin inhibitor recombinant 
receptor-associated protein bound to glutathione-S-transferase (RAP-GST). Because 
renin and prorenin are also known to be internalized via mannose 6-phosphate (M6P) 
receptors, binding and uptake were additionally studied in the presence of the M6P 
receptor antagonist M6P. Finally, we evaluated to what degree M6P interferes with 
megalin-mediated processes, making use of the fact that ciPTEC internalize bovine 
serum albumin (BSA) exclusively via megalin [10]. 
METHODS
Cell Culture 
The ciPTEC line was derived from a healthy donor [10]. Cells were cultured in 
phenolred-free DMEM/F12 (Invitrogen, Breda, the Netherlands) supplemented with 
10% (v/v) FCS (MP Biomedicals, Uden, The Netherlands), containing insulin (5 μg/
mL), transferrin (5 μg/mL), selenium (5 ng/mL), hydrocortisone (36 ng/mL), epithelial 
growth factor (10 ng/mL), and tri-iodothyronine (40 pg/mL). The cells were seeded at a 
density of 55000 cells per cm2 in 96- or 24-wells plates (Costar, Corning, New York, USA). 
They were cultured for 24 hours at 33°C and matured for 7 days at 37°C, in 5% CO2. 
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Prorenin and Renin Binding and Uptake  
To study prorenin and renin binding and internalization by ciPTECs, cells were 
incubated at 4°C or 37°C with 1000 U/L recombinant human prorenin and renin (a 
gift from Actelion Pharmaceuticals, Alschwill, Switzerland) diluted in phosphate buffer. 
Incubations lasted up to 24 hours, and were performed in 24-well plates in the ab-
sence or presence of M6P (10 mmol/L) and/or recombinant RAP-GST (100 μg/L). After 
incubation, the medium was removed, and the cells were washed three times with 
ice-cold Hank’s Balanced Salt Solution (HBSS). Then, the cells were lysed with ice-cold 
0.2% triton X-100, and centrifuged for 15 minutes at 4°C at 14000 rpm. Supernatants 
were collected and stored at -20°C. Immunoreactive renin in the supernatants was 
measured with the Renin III (Cisbio, Gif-sur-Yvette, France) immunoradiometric assay. 
Prorenin was also measured with this assay, after its conversion to the renin confor-
mation (allowing its detection in the assay) by incubating it with aliskiren [12, 13]. Pro-
renin measurements were performed both before and after aliskiren incubation, with 
levels being detected before aliskiren exposure representing prorenin that had been 
activated by the cells, and levels after aliskiren exposure representing the total amount 
of prorenin. 
Albumin Uptake 
To study whether M6P interferes with megalin-mediated uptake, cells were in-
cubated in a 96-well plate setup at 37°C with 10 μg/mL fluorescently labelled BSA (BSA 
Alexa Fluor™ conjugate, Invitrogen , Carlsbad, USA), in the absence or presence of M6P 
(1 mmol-100 mmol/L) or RAP-GST 1.5-200 μg/mL) for 4 hours [10]. During the last 10 
minutes, the Hoechst33342 stain (Life Technologies, Carlsbad, USA) was added to dye 
the nucleus. Then, the medium was removed, and the wells were washed with HBSS at 
room temperature. Florescence readings were performed using a CV7000S high-con-
tent imager (Yokogawa, Tokyo, Japan). 
Data Analysis
Results are shown as mean±SEM. Differences were tested using two-way ANO-
VA, followed by Bonferroni multiple comparison test. P<0.05 was considered signifi-
cant. Data below detection limit were assumed to equal the detection limit. 
RESULTS
Prorenin and Renin Binding and Uptake  
Incubating ciPTEC with either prorenin (Figure 1) or renin (Figure 2) at 37°C re-
sulted in a time-dependent increase in their cellular levels, a plateau being reached 
after 6-8 hours. The majority of cellular prorenin (up to 90%) was recognized as renin, 








suggestive for prorenin activation upon binding and/or internalization.  In contrast, 
following incubation at 4°C, the majority of prorenin was in its inactive form, and the 
steady-state levels of both renin and prorenin were ≈5-10-fold lower than those at 
37°C (Figures 1 and 2). At 37°C, M6P reduced cellular prorenin (P<0.05) and renin 
(P<0.01) accumulation by >80%, without altering the degree of prorenin activation. At 
4°C, the blocking effect of M6P was much more modest, significance being reached in 
the case of renin only (P<0.05).   
At 37°C, RAP-GST reduced cellular prorenin and renin accumulation after 8 
hours by >80%, both in the absence and presence of M6P (Figure 3). At 4°C, its block-
ing effects were more modest, particularly in the presence of M6P. 
Albumin Uptake 
Both M6P and RAP-GST blocked the uptake of labelled BSA at 37°C in a concen-
Figure 1.  Time-dependent increase in the cellular levels of total and activated 
prorenin after incubation with 1000 U/L of prorenin in the absence or presence of 
10 mmol/L M6P at 37°C or 4°C. Data (mean±SEM of 3-5 experiments) are expressed 
per mg of protein. Please note the difference in scale for the 37°C or 4°C data.
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tration-dependent manner, with IC50’s of ≈ 7 mmol/L and 140 μg/mL (corresponding 
with 21 mmol/L), respectively (Figure 4). 
DISCUSSION 
The aim of this study was to investigate megalin-mediated renin and prorenin 
uptake by ciPTEC. PT physiology involves complex mechanisms for substance trans-
porting. Until now, information about such transport arose from cell lines expressing 
at most a few of the many transporters physiologically present in the PT, while megalin 
endocytosis has been investigated predominantly in non-human cells [11]. ciPTEC 
express most of these transporters and efflux pumps, and possess the complete en-
docytosis machinery, thus making these cells a more appropriate model to study PT 
physiology [11].
The RAS is essential to maintain fluid-electrolyte homeostasis and blood pres-
sure regulation. Moreover, the RAS also participates in the pathophysiology of cardio-
vascular and renal diseases, and consequently, its blockade is currently the crux in the 
Figure 2.  Time-dependent increase in the cellular levels of renin after incubation 
with 1000 U/L of renin in the absence or presence of 10 mmol/L M6P at 37°C 
or 4°C. Data (mean±SEM of 3-5 experiments) are expressed per mg of protein
Figure 3. Cellular levels of prorenin (activated and total) and renin in the presence or absence 
of 10 mmol/L M6P and/or 100 μg/mL RAP-GST in ciPTEC exposed to prorenin or renin (both 
1000 U/L) at 37°C or 4°C. Data (mean±SEM of 3 experiments) are expressed per mg of protein








treatment of these pathologies [14, 15]. Recently, it has been suggested that urinary 
levels of RAS components, specifically renin and angiotensinogen, correlate to intrare-
nal RAS activity, thus making it possible to monitor hypertension worsening and kid-
ney function deterioration by simply measuring renin and/or angiotensinogen in 
urine [16, 17]. Yet, confusingly, although multiple studies suggest that angiotensino-
gen is synthesized in the PT (supporting the existence of an independent intrarenal 
RAS), renal angiotensin II generation turned out to depend exclusively on liver-derived 
angiotensinogen [18], i.e., it was not affected by renal angiotensinogen KO, both under 
normal and pathological conditions. If so, a renal angiotensinogen uptake process 
might be a prerequisite for renal angiotensin production, e.g. involving megalin-medi-
ated endocytosis [5]. Curiously, prorenin, which is undetectable in urine, has been de-
tected by Roksnoer et al. in urine of patients with Dent disease and Lowe syndrome, 
two disorders that are characterized by mutations that impair receptor-mediated en-
docytosis in the PT [9]. This suggests that, normally, prorenin is completely reabsorbed 
from urine via the megalin pathway. This is not the case for renin, since renin can be 
detected in urine at levels corresponding to 6-7% of its plasma levels [17]. Neverthe-
less, renin levels rose 20-40 fold in urine of patients with Dent disease and Lowe syn-
tration-dependent manner, with IC50’s of ≈ 7 mmol/L and 140 μg/mL (corresponding 
with 21 mmol/L), respectively (Figure 4). 
DISCUSSION 
The aim of this study was to investigate megalin-mediated renin and prorenin 
uptake by ciPTEC. PT physiology involves complex mechanisms for substance trans-
porting. Until now, information about such transport arose from cell lines expressing 
at most a few of the many transporters physiologically present in the PT, while megalin 
endocytosis has been investigated predominantly in non-human cells [11]. ciPTEC 
express most of these transporters and efflux pumps, and possess the complete en-
docytosis machinery, thus making these cells a more appropriate model to study PT 
physiology [11].
The RAS is essential to maintain fluid-electrolyte homeostasis and blood pres-
sure regulation. Moreover, the RAS also participates in the pathophysiology of cardio-
vascular and renal diseases, and consequently, its blockade is currently the crux in the 
Figure 2.  Time-dependent increase in the cellular levels of renin after incubation 
with 1000 U/L of renin in the absence or presence of 10 mmol/L M6P at 37°C 
or 4°C. Data (mean±SEM of 3-5 experiments) are expressed per mg of protein
Figure 3. Cellular levels of prorenin (activated and total) and renin in the presence or absence 
of 10 mmol/L M6P and/or 100 μg/mL RAP-GST in ciPTEC exposed to prorenin or renin (both 
1000 U/L) at 37°C or 4°C. Data (mean±SEM of 3 experiments) are expressed per mg of protein
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drome, in parallel with the levels of angiotensinogen. This finding, together with the 
close correlation between angiotensinogen and albumin levels in urine [9, 17, 19], ar-
gues against tubular secretion of renin and angiotensinogen, and rather suggests that 
these urinary components are derived from blood via glomerular filtration. 
In many studies with different cell types such as rat vascular smooth muscle 
cells, cardiomyocytes, fibroblasts, and human endothelial cells, it has been demon-
strated that besides megalin, M6P receptors also bind and internalize renin and pro-
renin [20-22]. Moreover, M6P receptor-mediated prorenin uptake resulted in prorenin 
activation, most likely as part of an intracellular clearance process, evidenced by the 
fact that we were unable to link this to intracellular angiotensin generation [21, 23]. In 
the current study, the M6P-induced decrease in prorenin and renin uptake by ciPTEC 
suggests that these cells also display M6P receptor-mediated uptake of renin and pro-
renin. Not surprisingly, the effect of M6P was best seen at 37°C, since at this tempera-
ture (but not at 4°C), M6P receptors cycle continuously between the cell surface and 
the intracellular compartment, thus allowing substantial (pro)renin accumulation in 
the cells. In contrast, at 4°C, renin and prorenin can only bind to cell surface M6P recep-
tors, without being internalized [24], nor can prorenin activation occur. Thus, at 4°C, 
cellular renin/prorenin accumulation is very limited, making it more difficult to show 
blockade of this effect by M6P.  
Two different M6PRs have been identified: the cation-independent type (or 
Figure 4. Inhibition of BSA uptake in ciPTEC by M6P and RAP-GST (top panels), and fluorescence 
staining representing BSA accumulation (bottom panels). Data (mean of 2-4 experiments) have 
been expressed as a percentage of control (cells incubated with BSA in the absence of inhibitor)








insulin-like growth factor II [IGFII] receptor) and the cation-dependent type. The IG-
FII/M6P receptor harbours two M6P binding sites, and is therefore able to bind to 
M6P-containing proteins, like renin and prorenin [20]. Interestingly, this receptor was 
also described as a ligand for the megalin receptor [25]. To what degree M6P itself 
acts as a ligand for the megalin receptor is unknown. Our results now show that the 
megalin inhibitor RAP-GST exerted identical effects as M6P (up to 90% inhibition of 
renin/prorenin uptake at 37°C, and a comparable, but much smaller effect at 4°C), and 
that both antagonists still exerted effects when added on top of each other. These data 
are suggestive for an interaction between megalin and M6P receptors and/or imply 
that M6P additionally blocks megalin-mediated pathways.  To evaluate the latter, we 
studied the effect of M6P on the uptake of BSA, a widely accepted megalin ligand [7]. 
Importantly, M6P not only blocked BSA uptake to the same degree as RAP-GST, but 
it also decreased RAP-GST endocytosis (data not shown). This therefore strongly sug-
gests that M6P is a megalin receptor blocker. 
In summary, ciPTEC bind and internalize renin and prorenin in a time- and tem-
perature-dependent manner. This process involves megalin and/or M6P receptors, 
and results in prorenin activation at 37°C. Both M6P and RAP-GST block this phenom-
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Renin-angiotensin system (RAS) blockade improves morbid-mortality in heart failure 
(HF) patients. Although the combination of angiotensin-converting enzyme inhibi-
tor (ACEi) with angiotensin II receptor blocker (ARB) or aliskiren blocks RAS more ef-
ficiently, the effect of dual RAS inhibition in HF patients is still controversial, and it 
has been associated with worsening of renal function. Since renal dysfunction (RD) 
in HF patients is frequent, investigating the effects of dual blockade of RAS in pa-
tients with HF and RD is crucial. We performed a systematic review and meta-anal-
ysis of randomized clinical trials in HF patients with RD treated with dual therapy 
to analyse death, cardiovascular (CV) death, HF hospitalization and adverse events. 
Cochrane, Embase, LILACS, PubMed and Web of Science were searched. Of 4,794 
screened records, 4 studies for quantitative analyses were included (13,641 patients). 
The meta-analysis demonstrated that dual RAS inhibition reduced the Hazard Ratio 
for death to 0.92 (p=0.07) and significantly diminished CV death or HF hospitaliza-
tion (p=0.0006) in patients with and without RD. Moreover, dual RAS blockade sig-
nificantly increased the risk for renal impairment (29%), hyperkalemia (32%), hypo-
tension (28%) and discontinuation of treatment due to these adverse events (3.14% 
versus 1.91% p=0.00001). This meta-analysis demonstrated that dual RAS blockade 
reduces the risk of CV death and HF hospitalization in patients with and without 
RD. Although the combination therapy increased the frequency of adverse events, 
few patients had to discontinue treatment. Therefore, dual RAS inhibition should 
not be categorically contraindicated, and cost-benefit ratio should be evaluated.
INTRODUCTION 
Heart failure (HF) is considered a public health burden affecting about 26 mil-
lion people worldwide [1]. In adults of emergent nations, the prevalence and incidence 
achieves 1–2% and 5–10 per 1,000 persons per year respectively [2]. In the USA and Eu-
rope, HF is a concern cause of morbid-mortality, and despite the evidence-based treat-
ment improves survival of HF patients, death and hospitalization rate remains high 
[3-4]. Recently, the European Society of Cardiology Heart Failure Long-Term Registry 
(ESC-HF-LT-R) involving 12,440 patients, showed an incidence of 14.5% for mortality or 
HF hospitalization within 1 year in chronic heart failure patients [5]. 
HF is commonly associated with other comorbidities, such as chronic kidney 
disease (CKD) [6-7]. For this reason, the prevalence of CKD in HF patients ranges from 
32 to 51% [7-11]. Also, the presence of CKD was a predictor of poor prognosis in HF, 
and the mortality was inversely proportional to the value of the estimated glomerular 
filtration rate (eGFR) [11]. 
The blockade of the Renin-Angiotensin System (RAS) with ACEi, ARBs or ali-
skiren has been widely used to treat HF, and for more than 20 years, it has improved 
the mortality and morbidity of these patients, decreasing the cardiovascular mortality 
and hospitalization in HF by 26% [12-13]. Notwithstanding, it is interesting to note that 
due to the presence of alternative RAS pathways, the blockade of RAS is not absolute 







when using a single drug [14-15]. In order to overcome this problem, several studies 
investigated whether the combination of RAS inhibitors can improve HF outcome [16-
20]. However, the potential benefit of the combination of these drugs to RAS inhibition 
remains to be elucidated [21]. 
So far, only two systematic reviews have examined the effect of dual versus sin-
gle drug RAS inhibition in morbidity and mortality in HF patients [22-23]. Upon analys-
ing 8 studies that included a total of 18,061 patients, Kuenzli et al. concluded that the 
combination of ACEi and ARBs reduced hospitalizations for HF, but not for all-cause 
hospitalizations, albeit the cardiovascular mortality has not been analysed. In another 
meta-analysis, it was observed that the dual blockade in HF patients did not improve 
either all-cause or cardiovascular mortality, although it did reduce HF hospitalizations. 
Both of them registered that dual therapy was associated with hyperkalemia, hypoten-
sion and renal impairment, suggesting that the risk-benefit ratio does not justify the 
association. In spite of that, this meta-analysis exhibits some limitations, since the effi-
cacy and safety parameters were examined in heterogeneous cohorts of patients [24], 
and also they did not evaluate the effects of dual blockade in HF and CKD patients. 
Here, in this systematic review and meta-analysis, we compared the effect of 
dual combination therapy (ARBs and ACEi or aliskiren and ACEi or ARBs) in HF patients 
with and without renal dysfunction (RD) in all-causes of death, CV death or HF hospi-
talization and adverse events. 
Methods 
This systematic review adheres to the Cochrane Collaboration methodology 
and was conducted following the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis PRISMA Checklist [25]. We registered this study on PROSPERO (Reg-
istration# CRD42015029351).
Information sources and search strategy 
A specific search was developed for each bibliography database (Supplemen-
tary Table S1): the Cochrane Library CENTRAL, Embase, LILACS (Latin American and 
Caribbean Health Sciences Literature), PubMed and Web of Science. The selection was 
supplemented including two clinical trial registry databases: ICTRP (WHO Internation-
al Clinical Trials Registry Platform) and NCT (number of clinical trials, deposit in the 
clinicaltrials.gov site), two databases of grey literature: Google Scholar and Open Grey, 
as well as manual search through the reference lists of the articles, included in the first 
phase. The search included articles published until March 16, 2017.
Study selection 
We included randomized clinical trials that investigated the dual blockade of 
RAS in HF patients and RD, defined as having an eGFR less than 60 mL/min/1.73m². 
The selection was carried out in two stages by two reviewers in an independent man-
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ner. In phase 1, in order to select articles that apparently met the selection criteria for 
inclusion, two authors (A.R.S. and A.G.M.) reviewed all titles and abstracts of the refer-
ences found. In phase 2, the same authors read the full text of all articles included in 
phase 1. The studies that did not meet the inclusion criteria were excluded with proper 
justification. In the absence of consensus between the two authors, the third reviewer 
(F.A.R.N.) acted as a mediator, to obtain the final decision. 
 Risk of bias and data collection 
The Cochrane Collaboration’s tool for Assessing risk of bias for randomized 
studies was applied. Information was accessed from previously published studies on 
protocols in order to accurately judge each domain proposed by the tool. In the ab-
sence of any data, the authors attempted to contact those responsible for the study. 
The author of this study contacted 19 authors for further information. Three authors 
responded, and one provided numerical data. All data collected were checked by the 
second author (A.G.M.) and reviewed by the third reviewer (F.A.R.N.). 
Summary measures 
All analyses were performed using the RevMan 5.3 software [26]. For time-
to-event outcomes (death, CV death or HF hospitalization,) the log hazard ratio and 
its standard error were calculated by the “generic inverse variance method” using 
fixed-effect model. The meta-analysis for adverse event outcome and the relative 
risk (RR) were assigned considering a 95% confidence interval, conducted by the Co-
chran-Mantel-Haenszel method, using random-effect model.
RESULTS 
Study selection and Study characteristics
We identified 6,447 references in the databases (Figure 1). The excluded articles 
were identified with the justifications properly described (Supplementary Table S2 and 
S3). Only 5 articles (ARIANA-CHF-RD 2015, ASTRONAUT 2013, ATMOSPHERE 2016, Val-
HeFT 2009 and Val-HeFT 2013) were included for the review, while 4 of them were 
selected for the quantitative analysis. The ARIANA-CHF-RD [19] study was not included 
in the quantitative analysis because it did not assess the death, CV death or HF hospi-
talization outcomes. In addition, it was not possible to combine it with other studies 
for the adverse event outcomes, since the study only conducted analysis on patients 
with RD, and the analysis of the adverse events was performed for all participants in-
dependent of renal function, due to lack of data in this group. All studies selected are 
randomized double blind clinical trials, published in English.
Table 1 shows the main characteristics of the studies included. The meta-analy-







sis was performed with the ASTRONAUT [20], ATMOSPHERE [27] and Val-HeFT [28-29] 
studies. Some studies the outcomes results did not have the group data with and with-
out renal disease.   
Risk of bias
A graph and summary of study quality are presented in Figure 2. The Cochrane 
Collaboration’s tool for assessing the risk of bias was applied (Appendix 1) for each 
study included, as “high,” “low” or “unclear”. To evaluate the quality of evidence and 
strength of recommendations, it was used the Grading of Recommendations, As-
sessment, Development and Evaluations (GRADE). (Supplementary Table S4).
Death
Initially, we performed a meta-analysis for death involving overall-population 
from The Val-HeFT, ATMOSPHERE and ASTRONAUT studies. This analysis pointed to a 
tendency to reduce death of patients using of the combined therapy, however with-
out statistical significance (p = 0.07; Figure 3 – A). Next, we compared the outcome of 
death for patients with RD (eGFR < 60 mL/min/1.73m²) versus without RD (≥ 60 mL/
min/1.73m²) in Val-HeFT and ATMOSPHERE studies, since ASTRONAUT study did not 
publish data separately for these groups. This analysis did not show a statistical differ-
ence between the group of patients with or without RD and the total effect was not 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cardiovascular death (CV) or heart failure (HF) hospitalization 
A meta-analysis of Val-HeFT (2013), ASTRONAUT (2013) and ATMOSPHERE 
(2016) demonstrated that dual blockade reduces the risk for CV death or HF hospi-
talization in 11% (p= 0.0006) (Figure 3 – C). Interesting, the benefit of dual blockade 
was similar between the subgroup of patients with RD and without RD. The risk for CV 
death or HF hospitalization in the subgroup of patients with RD and without RD was 
diminished by 14% and 9%, respectively (test for subgroup differences – p=0.44). The 
heterogeneity tests of the meta-analysis exhibited a Chi² = 7.43 df = 5 (P = 0.19) and I² 
= 33% suggesting an adequate homogeneity between the studies. 
Adverse Events and Discontinuation of therapy
Due to the lack of data reported for groups with and without RD, meta-analy-
sis of the adverse events was performed for the overall-population included. The out-
comes of hyperkalemia, hypotension, and renal impairment were assessed in ATMO-
SPHERE [27] and ASTRONAUT [20] studies, but not for the Val-HeFT study, since the 
data was not published in the latter study. To analyse the therapy discontinuation the 
data of Val-HeFT, 2001 study were included [16]. 
Dual RAS blockade therapy increased the risk of adverse events by 30% (29% 
to renal impairment; 32% to hyperkalemia and 28% to hypotension) (Figure 4 - A). 
Treatment discontinuation by adverse events was described by 3.14% with RAS dual 
blockade and 1.91% in monotherapy. The risk for patients using dual RAS blockade in-
creased in 1.69 (p < 0.00001): 1.93 to renal impairment, 1.94 to hyperkalemia and 1.63 
to hypotension  (Figure 4 - B).
Figure 2.  Risk of bias graph and summary: review authors’ judgements about 
each risk of bias item presented as percentages across all included studies
Chapter 6
104
Figure 3 . (A) Meta-analysis of death with overall patients independent of renal function. 
(B) Meta-analysis of death with the subgroups according to the estimated glomerular 
filtration rate: renal dysfunction (eGFR <60ml/min/1.73 m2) versus without renal 
dysfunction (eGFR <60ml/min/1.73 m2. (C) Meta-analysis of cardiovascular (CV) death 
or heart failure (HF) hospitalization with overall patients and the subgroups according 
to eGFR: renal dysfunction (eGFR <60ml/min/1.73 m2) versus without renal dysfunction 
(eGFR <60ml/min/1.73 m2. The name and year of the studies are presented followed 
by weight of each study and the Hazard Ratio (HR) with 95% confidence interval (CI)








 Summary of evidence 
The importance of the RAS blockade in the treatment of HF is unquestionable. 
RAS inhibition can be achieved by isolated use of ACEi, ARBs, or aliskiren. Additionally, 
the combination therapy with two or more of these drugs is an interesting strategy to 
inhibit the RAS more significantly, since it overcomes alternative pathways for angio-
tensin II generation [14-15]. Nevertheless, this combination increases the risk of some 
Figure 4. (A) Meta-analysis of adverse events and (B) discontinuation of treatment 
by renal impairment, hyperkalemia, and hypotension involving with overall 
patients independent of renal function. The graph shows the name and year of the 
studies followed by the number of events and the total number of participants.
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adverse effects such as renal impairment [22,23-30], and brings some concerns wheth-
er the risk-benefit ratio justifies the combination therapy. Although 30-40% of heart 
failure patients have renal dysfunction, to our knowledge, the impact of RAS inhibition 
with combined therapy was not investigated in patients with both disease (HF and 
RD). Here we described the first systematic review and meta-analysis to examine the 
effect of dual RAS blockade in patients with heart failure and renal disease. 
Only five articles were included for the review [19,20,27-29], while 4 of them 
were selected for the quantitative analysis. One study exhibited the results with dual 
blockade using the combination ARBs and ACEi, and two other with aliskiren and 
ACEi/ARBs.
The meta-analysis displayed that the dual blockade did not reduced the over-
all-population death outcome, although there was a beneficial tendency in favor of 
drug therapy combination (p=0.07) (Figure 3- A). This result is similar to previously me-
ta-analysis [22-23], however we must consider that these former meta-analyses did 
not include the results of the ATMOSPHERE [27] and ASTRONAUT [20] studies, in which 
the dual RAS blockade occurred with the addition of aliskiren to the therapy. 
Next, we compared the role of dual RAS inhibition in the subgroups with and 
without renal dysfunction, and the meta-analysis exhibited a similar result that was 
observed in overall population, since death outcome was not statistically significant, 
between these groups (p=0.16) (Figure 3 - B). It was not possible to include the AS-
TRONAUT [20] study in this analysis, because the results were not published for the 
subgroup with and without RD for that outcome
To further investigate whether dual RAS blockade can display a positive impact 
in HF patients, we examined the CV death or HF hospitalization. Our results demon-
strated that RAS dual-blockade significantly reduced the risk of CV death or HF hos-
pitalization by 11% (p= .0006). Interesting, the favorable effect of combination RAS 
inhibitors was observed in patients with and without RD, since it reduced the hazard 
ratio in 14% and 9% respectively (Figure 3- C). As a result, the benefit effect of RAS 
dual-blockade treatment did not differ due to eGFR. 
Our meta-analysis enlightens the controversies of the effect of dual RAS block-
ade in the treatment of HF patients. Val-HeFT study displayed a benefit in favor of the 
combination therapy [16]. On contrary, the ASTRONAULT and ATMOSPHERE studies 
did not support the same finding [20,27]. The explanation for theses discrepancies is 
not clear. An element that could influence would be the reduced percentage of pa-
tients in use of beta-blockers (34.5%) and mineralocorticoid receptor antagonists (5%) 
in the Val-HeFT study (Table 1), when compared to ASTRONAUT (81.7% and 55.4 % 
respectively) and ATMOSPHERE (92.0% and 36.6%, respectively) [16,20,27,29]. 
The effect of RAS dual blockade in reducing CV death or HF hospitalization in 
heart failure patients in our meta-analysis cannot be attributed to the sample size 
weighting differences in the aforementioned studies. The sample size weighting of Val-
HeFT (22.7%) study in the subgroup with RD was larger than ASTRONAUT [20] (5.2%) 
and ATMOSPHERE [27] (13.8%), but in the subgroup without RD, Val-HeFT (19.5%) was 
smaller than ATMOSPHERE (32.6%) (Figure 3-C). 







Interestingly, another randomized study with dual-blockade using ARB (cande-
sartan) and ACEIs (CHARM-added) in patients with HF registered benefit for CV death 
or HF hospitalization, HR 0.85 (0.75 - 0.96; 95% CI and p 0.01) [15]. In the group can-
desartan combined with the ACE inhibitor, 55% were in the use of beta-blocker and 
17.4% in the mineralocorticoid receptor antagonists at baseline, and 33% of the pa-
tients had an eGFR <60mL/min/1.73m². Unfortunately, the results of the subgroups 
with and without RD were neither published nor available for analysis [18].
The observation of the favorable results of the Val-HeFT (31) and CHARM-add-
ed [18] studies for the use of RAS dual-blockade with BRA and ACEi, in contrast to the 
results of the ASTRONAUT [20] and ATMOSPHERE [27] studies, in which aliskiren was 
also added, may suggest pharmacological differences in the RAS inhibition pathway. 
Both ARB and ACEi elevate the levels of angiotensin 1-7 (the product of angiotensin 
I and II degradation) [31-32], whereas aliskiren, by the upstream blocking of the RAS, 
does not increase, and may even decrease the concentration of this peptide [33]. Since 
angiotensin 1-7 antagonizes the deleterious actions of angiotensin II, favoring a vaso-
dilator and anti-proliferative action, displaying cardioprotection in animal models, it is 
conceivable that combined use of ARB and ACEi justifies the favorable results of the 
Val-HeFT [29] and CHARM-Added [18] studies but not in ASTRONAUT [20] and ATMO-
SPHERE [21] studies.
In order to analyse this possibility, we performed a multiple treatment me-
ta-analysis comparing studies that use the dual-blockade with ARB combined with 
ACEi (CHARM-added [18], VALIANT [17] and Val-HeFT) [29] versus studies using ali-
skiren added (ASPIRE [34], ASTRONAUT [20] and ATMOSPHERE [27]). The results of the 
CHARM-added, VALIANT and ASPIRE studies were now included for this analysis. The 
results (Figure 5) demonstrated a 9% (p=0.010) risk reduction for CV death or HF hos-
pitalization in patients treated with dual-blockade. Nonetheless, this meta-analysis did 
not observe a difference between the group of patients treated with ABR plus ACEI vs. 
aliskiren with ACEi/ARB, as the test for subgroup difference effect on the treatment 
was not significant. It is important to mention that this analysis was not the main ob-
jective of the present study.
The results for all adverse events assessed were also not favorable to the use of 
the dual-blockade treatment (Figure 4). The meta-analysis for adverse events (Figures 
4-A) exhibited that there was a 29% increased risk for renal impairment, 32% for hy-
perkalemia, and 28% for hypotension in patients using dual-blockade therapy when 
compared to monotherapy. The analysis of treatment discontinuation due to adverse 
effects (Figure 4-B) demonstrated that the combination therapy led to 3.59% (vs. 
2.34%) discontinuation due to renal impairment, 3.37% (vs.1.72%) for hyperkalemia 
and 2.56% (vs. 1.58%) for hypotension.
These results clearly demonstrate that dual-blockade therapy increases the risk 
of adverse effects. However, considering that the meta-analysis for CV death or HF 
hospitalization suggests a beneficial effect within the association of ARB and ACEi or 
the addition of aliskiren to ARB/ACEI, it is recommended to evaluate the cost-benefit 
ratio on each patient, since these adverse effects can be monitored by routine exams.
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A new proposal for the dual RAS blockade in HF patients is currently being ad-
dressed with the novel angiotensin-neprilysin novel inhibitor LCZ696 (Sacubitril and 
Valsartan) [35]. The PARADIGM-HF study evidenced superiority of LCZ696 vs. enalapril 
in terms of death and hospitalization for heart failure, displaying a 20% risk reduction 
in death from cardiovascular causes or hospitalization for heart failure with similar re-
sults between groups with eGFR higher or lower than 60 mL/min/1.73m². The LCZ696 
group had higher proportions of patients with hypotension and non-severe angioede-
ma, but lower proportions of renal impairment, hyperkalemia, and cough when com-
pared to the enalapril group [35].
Quality assessment
The risk assessment of bias by the Cochrane Collaboration tool for assessing risk 
of bias [36] (Figure 2) was mostly graded as low risk of bias. The evaluation of GRADE 
ranged from moderate to high according to the outcomes analysed (Table S4). Thus, 
these evaluations did not show important biases that could affect the interpretation 
of the meta-analysis results [37].
There was only one trial evaluated as high risk of bias (domain of selective re-
porting) for the Val-HeFT study (2013). However, this assessment was due to the lack 
of pre-specification in the protocol regarding CV death or HF hospitalization outcome 
[29]. Nevertheless, we cannot discard this study result for this reason, since its protocol 
was established within the analysis of death outcomes and morbid events. In addition, 
despite some differences among the studies, the main clinical characteristics of the 
Figure 5. Multiple treatment meta-analysis to compare ARB combined with ACE inhibitors versus 
and aliskiren combined with ARB/ACEi on the effect of dual-blockade on cardiovascular death 
(CV) or heart failure (HF) hospitalization. The name and year of the studies are presented followed 
by the by weight of each study and the Hazard Ratio (HR) with 95% confidence interval (CI) 







participants are similar for performing the meta-analysis.
Limitations 
The limitations to be pointed out is the small number of studies available in the 
literature that have evaluated subgroups of patients with HF and RD. An additional 
limitation is that the results extracted for this review analyse subgroups of random-
ized clinical trials involving HF patients. Initially in the protocol of this review, it was 
planned to analyse patients with HF and concomitant chronic kidney disease, howev-
er, most of the studies did not evaluated the presence of proteinuria and normal eGFR.
There was also a variation of the average follow-up of the participants among 
the studies (Table 1). The lowest being the ARIANA-CHF-RD [19] with 6.1 months, AS-
TRONAUT [20] with 11.3 months, Val-HeFT with 23 months while the largest was the 
ATMOSPHERE with 36.6 months [19,20,27].
Conclusions  
The present meta-analysis demonstrated that the use of dual RAS blockade in 
patients with heart failure and renal dysfunction reduces the risk of CV death and HF 
hospitalization by 11%. Furthermore, this benefit remains in patients with and without 
renal dysfunction. Even though the combination of RAS inhibition therapy increase 
the risk of adverse events such as hypotension, hyperkalemia, and renal impairment, 
only a small percentage of patients had to discontinue the treatment.
This meta-analysis contributes to the discussion whether dual RAS blockade in 
patients with heart failure and renal dysfunction should be recommended. Clinicians 
might be aware that dual RAS blockade in HF may not be categorically contraindicated 
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Supplementary Table S4. Summary of the evaluation of the quality of evidence, 
according to GRADE (Grading of Recommendations Assessment, Development and 
Evaluation). a. The risk of bias in the report of high selective outcome for the Val-HeFT 
study. b. Meta-analysis with inconsistency. I² = 76%; c. Meta-analysis with moderate 
inconsistency. I² = 56%.
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More than a century has passed since the discovery of renin by Tigerstedt and 
Bergman in 1898. From that moment, research on the renin-angiotensin system (RAS) 
has never stopped growing, and notably, renin assumed a prominent position, as it 
is responsible for the first and rate-limiting step of the RAS cascade. It is now well-es-
tablished that the RAS is a major player in blood pressure regulation and fluid elec-
trolyte homeostasis, besides its participation in the pathophysiology of renal and car-
diovascular diseases. Nevertheless, despite the extensive knowledge acquired so far, 
renin-producing cells (RPC) are still a conundrum, and only recently, these cells are 
starting to be deciphered. This thesis focused on RPC, their plasticity, novels aspects 
and function, beyond perspectives and insights related to these unique cells.
Chapter 1 provides a broad review about the current knowledge on RPC. It 
summarizes not only classical concepts like the so-called “recruitment” phenomenon, 
growth and developmental processes, but also novel contexts such as inflammation, 
cell repair mechanisms and tissue regeneration. Chapter 2 describes a new approach 
to understand RPC biology. It is the first report of a gene expression catalogue of hu-
man renin-producing tumors, or reninomas, that culminated in the discovery of 36 
genes that are new to the RPC gene signature. Noteworthy, the cell models available 
to study RPC are mouse-derived, and therefore, proper knowledge of human RPCs 
is limited, relying on speculation on the basis of murine models. This fact makes our 
approach unique, and furthermore, among the genes identified, the platelet-derived 
growth factor (PDGF) β - PDGF β receptor  signaling pathway was revealed as a prom-
ising RPC regulator.  
In chapter 3, we investigated the existence of the brain RAS, whose activity 
relies on the assumption that local (pro)renin synthesis by RPC would be a sine qua 
non condition, since the presence of the blood-brain barrier would preclude (pro)renin 
uptake from blood by central nervous system cells. We were unable to find evidence 
to support the aforementioned concept. Instead, our data suggest that renin in the 
brain represents trapped plasma renin and/or locally activated trapped plasma pro-
renin. These findings uphold the conception that RPC in the kidney are the only renin 
source in the body.     
Chapter 4 discusses the plausibility of ‘open’ prorenin (prorenin in an open 
conformation, capable of displaying angiotensin-generating activity) release by renin 
and/or prorenin-synthesizing cells. After many decades, prorenin’s physiological role 
remains a riddle: is it just renin’s inactive precursor or more than that? Juxtaglomerular 
cells (JGC), i.e. RPC located at the juxtaglomerular apparatus, are the main source of 
prorenin and the only source of renin in circulation under unstressed conditions. In 
addition, other tissues are also able to synthesize and release prorenin. Under physio-
logical conditions (pH 7.4, 37°C), prorenin is present in a ‘closed’ conformation, which 
cannot result in angiotensin generation. We speculated that prorenin might exert local 
angiotensin-generating effects, at the site of its release, provided that is released in an 
open conformation from prorenin-synthesizing cells, before returning to the closed 







conformation in the extracellular milieu. Our in-vitro study did not reveal any evidence 
to support this conjecture, and, thus, at least under cell culture conditions, RPC and 
other prorenin-synthesizing cells do not release open (active) prorenin.
Chapter 5 investigates renin and prorenin reabsorption by human condition-
ally immortalized proximal epithelial tubule cells (ciPTEC). The reabsorption of RAS 
components like angiotensinogen, renin and prorenin occurs in the kidney proximal 
tubule, in a megalin-dependent manner, and may underlie renal angiotensin produc-
tion. Patients with Dent’s disease or Lowe syndrome (resulting in impaired megalin 
function) exhibit an increase in urinary renin and angiotensinogen levels, suggestive 
for diminished reabsorption. Strikingly, the defective reabsorption also allowed the 
detection of urinary prorenin, which is normally undetectable. We demonstrated that 
ciPTEC bind and internalize renin and prorenin in a temperature-dependent manner, 
resulting in prorenin activation at 37°C. This process involved megalin and/or man-
nose-6-phosphate (M6P) receptors, and surprisingly, the M6P receptor antagonist 
M6P interfered with megalin endocytosis. 
RAS blockade is a cornerstone in the treatment of cardiovascular and renal 
diseases. In chapter 6, we performed a systematic review and meta-analysis of ran-
domized clinical trials in patients with concomitant heart failure and renal dysfunction 
under dual RAS blockade to analyze death, cardiovascular death, heart failure hospi-
talization and adverse events such as worsening in renal function, hypotension and 
hyperkalemia. Even though the number of available trials was limited, our analysis 
supports the potential benefits of dual RAS blockade, despite the increased frequency 
of adverse events. Dual RAS inhibition might therefore be used cautiously in certain 
patient groups, of course keeping in mind that chronic RAS blockade triggers RPC “re-
cruitment” along the afferent arteriole. 
FUTURE PERSPECTIVES
Beyond the main function of the RAS as the major regulator of blood pressure 
and fluid electrolyte homeostasis, RPCs play a much more in-depth role than simply 
producing and releasing renin. Their huge phenotypical plasticity, exemplified in the 
“recruitment phenomenon”, allows them to work as pluripotent progenitors for differ-
ent kidney cell types. 
Just recently, RPCs have been connected to tissue regeneration, inflammation 
and possibly fibrosis. Interestingly, our findings have revealed the PDGF β - PDGF β 
receptor  signaling pathway as a potential regulator of the RPCs expression, able to 
shift their classical renin phenotype into an inflammatory phenotype. Yet, PDGF β is a 
pericyte marker, and the latter cells are known to wrap vascular walls and to possess a 
high phenotypical plasticity. Not surprisingly, RPCs are able to differentiate into peri-
cytes and vice versa.
It’s noteworthy that our findings do not support the concept of extrarenal sites 
of renin production, in particular in the brain. Multiple papers have speculated about 
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(pro)renin production in the brain, possibly intracellularly, and about locally synthe-
sized prorenin displaying activity following its binding to the brain (pro)renin receptor. 
However, no paper actually quantified brain (pro)renin in an appropriate manner. Our 
data now support that there is no (pro)renin in the brain except for the small amounts 
of renin and prorenin in trapped blood in brain tissue (which disappeared after buf-
fer perfusion), thus arguing strongly against angiotensin production at brain tissue 
sites. Even if prorenin is released locally (e.g., in the ovary), we were unable to show 
that such prorenin would display activity at its site of release. Together with the recent 
insight that the (pro)renin receptor has functions beyond the RAS, and is unrelated 
to prorenin activation, this implies that we need to find novel mechanisms support-
ing a role for prorenin, if any, in local angiotensin generation. Thus, JGC firmly remain 
the only source of renin in the body, on which angiotensin generation depends, and 
whether prorenin generates angiotensins locally under physiological or even patho-
logical conditions remains to be proven. 
Within the kidney, apart from JGC, also tubular cells have been proposed to syn-
thesize prorenin. Surprisingly, angiotensin stimulates rather than inhibits this produc-
tion (positive feedback, as opposed to its negative feedback in JGC), and there is no ev-
idence for tubular renin production. To what degree this prorenin truly contributes to 
intrarenal angiotensin generation is still controversial; it was even suggested to act on 
angiotensinogen of tubular origin, for instance when bound to the (pro)renin receptor. 
Yet, making use of transgenic rodents not expressing renal angiotensinogen it became 
clear that renal angiotensin production depends entirely on plasma-derived angio-
tensinogen, i.e., angiotensinogen of hepatic origin. Studies in patients with defective 
proximal tubular reabsorption support megalin-dependent reabsorption of filtered 
angiotensinogen, as well as renin and prorenin, and our current ciPTEC data allow a 
detailed insight into the mechanism of this phenomenon. Unexpectedly, there may 
be an additional role for M6P receptors in the reabsorption process, and/or M6P itself 
blocks megalin-mediated processes. Considering the massive (up to 40-fold) rise in 
RAS components levels in urine in patients with Dent’s disease or Lowe syndrome, the 
idea of tubular synthesis and release of renin, prorenin and/or angiotensinogen needs 
to be reconsidered. Most likely, changes in urinary (pro)renin and angiotensinogen 
levels reflect changes in megalin-dependent reabsorption (regulated, among others, 
by angiotensin!) instead of independent tubular release of RAS components. 
The benefit of RAS blockade in cardiovascular and renal disease is indisputed, 
but what is still controversial is the optimal degree of RAS blockade. A high degree of 
RAS blockade may have additional beneficial effects, but also results in a higher inci-
dence of side effects. The degree of blockade can be estimated from the increase in 
circulating renin, depicting the “recruitment” of new RPC along the afferent arterioles. 
The long-term consequences of this process are still unknown, nor do we known if it 
contributes to renal impairment in the future. Besides renin production, RPC would 
participate directly in the concentric vascular  hypertrophy, despite the control of the 
blood pressure levels. Furthermore, many questions remain unanswered. Would these 
cells contribute to a fibrosis process, leading to architecture disruption and extracel-







lular matrix production? If these cells possess tissue repair mechanisms, why are they 
switched off or dysfunctional? To what degree is tissue regeneration truly effective 
to restore the normal function? Would such regeneration be persistent or transient? 
Answering these questions, combined with a full understanding of local (renal) angio-
tensin production will ultimately allow more effective anti-hypertensive therapies, and 




In 1898, meer dan een eeuw geleden, werd renine ontdekt door Tigerstedt en 
Bergman. Vanaf dat moment is het onderzoek naar het renine-angiotensine systeem 
(RAS) continu gegroeid, en met name renine heeft hierin een prominente positie inge-
nomen, daar dit enzym verantwoordelijk is voor de eerste en  snelheidsbepalende 
stap in de RAS keten. Inmiddels staat vast dat het RAS een belangrijke rol speelt in de 
bloeddrukregulatie en vloeistof- en elektrolythuishouding, naast het leveren van een 
bijdrage aan de pathofysiologie van nierziekten en hart- en vaataandoeningen. Echter, 
ondanks de gedetailleerde kennis die tot nu toe is opgedaan, zijn renine-produceren-
de cellen (RPC) nog steeds een raadsel, en pas recentelijk is men begonnen met het 
ontrafelen van deze cellen. Dit proefschrift richt zich op RPC, hun plasticiteit, nieuwe 
aspecten en functies, naast diverse andere inzichten in relatie tot deze bijzondere cel-
len.
Hoofdstuk 1 biedt een breed overzicht van de huidige kennis omtrent RPC. Het 
beschrijft niet alleen het zgn. “recruitment” fenomeen (het aanzetten van RPC op grote 
schaal), maar toont ook aan dat deze cellen een rol spelen bij ontsteking, cel-reparatie-
mechanismen en weefselvernieuwing. Hoofdstuk 2 beschrijft een nieuwe aanpak om 
de RPC biologie beter te begrijpen. Het is de eerste rapportage van een genexpressie 
catalogus van humane renine-producerende tumoren, of reninoma’s, welke geresult-
eerd heeft in de ontdekking van 36 genen die representatief zijn voor RPC. Hierbij moet 
opgemerkt worden dat de tot dusver beschikbare celmodellen voor de bestudering 
van RPC zijn afgeleid van de muis, waarbij de relevantie voor de mens twijfelachtig is. 
Dit maakt onze aanpak uniek en bovendien bleek onder de geïdentificeerde genen 
platelet-derived growth factor (PDGF) β een veelbelovende RPC regelaar te zijn.  
In hoofdstuk 3 onderzochten we het bestaan van het RAS in de hersenen, waar-
van de activiteit is gebaseerd op de aanname dat lokale (pro)renine synthese door RPC 
een sine qua non conditie is, aangezien de aanwezigheid van de bloed-hersen barrière 
de opname van (pro)renine uit het bloed door cellen van het centraal zenuwstelsel in 
de weg zou staan. We konden echter geen bewijs  voor dit concept vinden. In plaats 
daarvan suggereren onze data dat renine in de hersenen gewoon het renine is dat in 
bloed voorkomt, aangezien hersenweefsel ook bloed bevat. Dit betekent dat RPC in de 
nieren de enige bron voor renine in het lichaam zijn.     
Hoofdstuk 4 bespreekt de mogelijkheid van ‘open’ prorenine (prorenine in 
een open conformatie, in staat tot angiotensine vorming) afgifte door renine en/of 
prorenine-synthetiserende cellen. Na vele decennia blijft de fysiologische rol van pro-
renine een mysterie: is het alleen renine’s inactieve voorvorm of is het meer dan dat? 
Juxtaglomerulaire cellen (JGC), dat wil zeggen RPC die zich in het juxtaglomerulaire 
apparaat bevinden, zijn de belangrijkste bron van prorenine en de enige bron van 
renine in de bloedsomloop onder normale omstandigheden. Diverse andere organen 
zijn ook in staat om prorenine te synthetiseren en af te geven aan het bloed. Onder fys-
iologische omstandigheden (pH 7.4, 37°C) is prorenine  aanwezig in een ‘gesloten’ con-
formatie, hetgeen niet kan leiden tot de vorming van angiotensine. We speculeerden 







dat prorenine mogelijk lokaal  angiotensine kan vormen, op de plaats waar het wordt 
uitgescheiden, mits deze afgifte geschiedt in een open conformatie voordat het ter-
ugkeert naar de gesloten conformatie in de extracellulaire ruimte. Onze in-vitro studie 
leverde echter geen bewijs op dat deze aanname ondersteunt, en daarom, in ieder 
geval onder celkweek-omstandigheden, lijkt er geen afgifte van open prorenine door 
RPC en andere prorenine-synthetiserende cellen te geschieden.
Hoofdstuk 5 onderzoekt de reabsorptie van renine en prorenine door prox-
imale tubulus epitheelcellen uit de nier van de mens. De reabsorptie van RAS com-
ponenten, zoals angiotensinogeen, renine en prorenine, vindt plaats in de proximale 
tubulus van de nier, via het eiwit megaline, en dit proces ligt mogelijk ten grondslag 
aan de produktie van angiotensine in de nier. Patiënten met een verstoorde megaline-
functie hebben sterk verhoogde renine en angiotensinogeen spiegels in hun urine, 
wat lijkt te wijzen op een verminderde reabsorptie. Het is opvallend dat een dergelijke 
verstoorde reabsorptie ook leidt tot de detectie van prorenine in de urine, hetgeen 
normaliter niet meetbaar is. We vonden dat de epitheelcellen renine en prorenine op 
een temperatuur- en tijdsafhankelijke manier internaliseerden, waarna bij 37°C pro-
renine in de cel werd omgezet in renine. Zowel megaline als mannose-6-fosfaat (M6P) 
receptoren zijn hierbij betrokken, en onverwacht bleek de M6P receptor antagonist 
M6P ook megaline-afhankelijke endocytose te blokkeren.  
Blokkade van het RAS staat centraal bij de behandeling van cardiovasculaire 
aandoeningen en nierziekten. In hoofdstuk 6  hebben we alle studies in patiënten 
met gelijktijdig hartfalen en nierdysfunctie onder duale RAS blokkade (i.e., die 2 RAS 
blokkers tegelijk kregen) geanalyseerd om tot een uitspraak te komen of de gun-
stige cardiovasculaire effecten van een dergelijke krachtige RAS blokkade opwegen 
tegen de bijwerkingen (dood, ziekenhuisopname, verslechtering van de nierfunctie, 
hypotensie en hyperkaliëmie). Hoewel het aantal beschikbare studies beperkt was, 
ondersteunt onze analyse de potentiële voordelen van duale RAS blokkade, ondanks 
de toegenomen frequentie van bijwerkingen. Duale RAS remming kan daarom voor-
zichtig gebruikt worden bij bepaalde groepen patiënten, uiteraard rekening houdend 
met het feit dat chronische RAS blokkade RPC “recruitment” induceert. 
TOEKOMSTPERSPECTIEVEN
Naast de hoofdfunctie van het RAS als de belangrijkste regelaar van de bloed-
druk en water- en electrolythuishouding, spelen RPC een veel diepgaandere rol dan 
simpelweg het produceren en afgeven van renine. Hun enorme fenotypische plas-
ticiteit, geïllustreerd door het “recruitment” fenomeen, stelt hen in staat om te werken 
als pluripotente stamcellen voor verschillende celtypen in de nier. 
Onlangs is er een relatie gevonden tussen RPC en weefselregeneratie, ont-
steking en mogelijk fibrose. Het is hierbij interessant dat onze bevindingen de pro-
fibrotische factor PDGF β als een mogelijke regelaar van de expressie van RPC laten 
zien. Tevens is PDGF β een marker voor pericyten, en van de laatstgenoemde cellen 
is bekend dat zij aanwezig zijn in de vaatwand en een grote fenotypische plasticiteit 
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bezitten. Het lijkt daarom geen verrassing dat RPC kunnen differentiëren tot pericyten 
en vice versa.
Onze bevindingen bieden geen ondersteuning aan het concept dat er renine 
geproduceerd wordt buiten de nieren, in het bijzonder in de hersenen. In vele artike-
len is gespeculeerd over de produktie van (pro)renine in de hersenen, mogelijk intra-
cellulair, en over lokaal gesynthesiseerd prorenine dat activiteit vertoont nadat het 
zich gebonden heeft aan de (pro)renine receptor in de hersenen. Geen enkel artikel 
heeft echter daadwerkelijk (pro)renine in de hersenen gekwantificeerd. Onze data 
tonen nu aan dat er geen (pro)renine in de hersenen is, op de kleine hoeveelheden 
renine en prorenine na die zich nu eenmaal bevinden in het beetje bloed dat zich in 
hersenweefsel bevindt (wat verdwijnt na buffer-perfusie), en dit is een sterk argument 
tegen de produktie van angiotensine in hersenweefsels. Zelfs als prorenine lokaal 
wordt afgegeven (bijvoorbeeld in de eierstokken), waren wij niet in staat om aan te 
tonen dat dit prorenine activiteit vertoonde op de plek van afgifte. Samen met het re-
cente inzicht dat de (pro)renine receptor functies heeft die niets met het RAS te maken 
hebben, impliceert dit dat we nieuwe mechanismen moeten vinden om te begrijpen 
hoe prorenine bijdraagt aan de lokale produktie van angiotensine. Derhalve blijven 
JGC vooralsnog de enige bron van renine in het lichaam, waarvan de produktie van 
angiotensine volledig afhangt. Of prorenine lokaal angiotensine aanmaakt onder fysi-
ologische, of zelfs pathologische omstandigheden, moet nog bewezen worden. 
In de nieren is geopperd dat naast JGC ook tubulus cellen prorenine synthe-
tiseren. Opmerkelijk genoeg heeft angiotensine op deze produktie juist een stimuler-
end effect (positieve feedback, in tegenstelling tot de negatieve feedback in JGC), en 
is er geen bewijs voor de produktie van renine in de tubulus. In hoeverre dit prorenine 
daadwerkelijk bijdraagt aan angiotensine produktie in de nieren is nog niet duidelijk; 
mogelijk vertoont het een interactie met  angiotensinogeen afkomstig uit de tubulus, 
bijvoorbeeld na binding aan de (pro)renine receptor. Het gebruik van transgene dieren 
die geen angiotensinogeen konden maken in hun nieren maakte echter duidelijk dat 
de angiotensine produktie in de nier volledig afhankelijk is van gefilterd angiotensino-
geen uit plasma, dat wil zeggen: angiotensinogeen van hepatische oorsprong. Studies 
in patiënten met een verstoorde reabsorptie in de proximale tubulus ondersteunen 
het concept van megaline-afhankelijke reabsorptie van gefilterd angiotensinogeen, 
renine en prorenine, en onze huidige data in epitheelcellen laten gedetailleerd zien 
welk mechanisme hieraan ten grondslag ligt. Verrassend genoeg blijkt dat er mogelijk 
een bijkomende rol is weggelegd voor M6P receptoren in het reabsorptieproces, en/
of dat M6P zelf de megaline-gemedieerde processen remt. Gezien de enorme stijging 
van de hoeveelheid RAS componenten in urine (tot 40-voudig)  in patiënten met een 
verstoorde megaline functie, moet het idee van synthese en afgifte van renine, pro-
renine en/of angiotensinogeen in de tubulus heroverwogen worden. Hoogstwaar-
schijnlijk wijzen veranderingen (pro)renine- en angiotensinogeen spiegels in urine op 
veranderingen in megaline-afhankelijke reabsorptie (gereguleerd, onder andere, door 
angiotensine!) in plaats van onafhankelijke afgifte van RAS componenten vanuit de 
tubulus.







De voordelen van RAS blokkade bij cardiovasculaire aandoeningen en nier-
ziekten zijn onbetwist, maar hoeveel blokkade optimaal is, is nog altijd onbekend. 
Een hoge mate van RAS remming kan leiden tot gunstiger effecten, maar resulteert 
ook in een hogere prevalentie van bijwerkingen. De mate van remming kan worden 
ingeschat op basis van de toename van renine in het bloed, een parameter voor de 
“werving” van nieuwe RPC. De lange termijngevolgen van dit proces zijn nog onbek-
end, noch weten we of het bijdraagt aan toekomstige nierfunctiestoornissen. Naast 
de produktie van renine, zouden RPC ook direct kunnen bijdragen aan vasculaire  hy-
pertrofie, zelfs als de bloeddruk normaal is. Nog altijd zijn vele vragen onbeantwoord. 
Dragen deze cellen bij aan het fibroseproces? Indien deze cellen weefsel-herstelcapac-
iteit bezitten, waarom zijn ze dan soms uitgeschakeld of dysfunctioneel? In hoeverre 
is weefselherstel daadwerkelijk effectief bij het herstellen van de normale functie? Zou 
dit herstel voortdurend plaatsvinden of is het van tijdelijke aard? Het beantwoorden 
van deze vragen, evenals een volledig begrip van de lokale angiotensine produktie 
(in de nieren), zal uiteindelijk leiden tot meer effectieve antihypertensieve therapieën, 
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